

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:56:16 ON 23 NOV 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Nov 2004 VOL 141 ISS 22
 FILE LAST UPDATED: 22 Nov 2004 (20041122/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>
 => d stat que
 L2 2 SEA FILE=REGISTRY ABB=ON PLU=ON "HYDROXYCITRIC ACID"/CN
 L6 78601 SEA FILE=HCAPLUS ABB=ON PLU=ON (ANTIHYPERTENSIVES/CV OR ANTIHYPERTENSIVE/CV OR "ANTIHYPERTENSIVE AGENT"/CV OR "ANTIHYPERTENSIVE AGENTS"/CV OR "ANTIHYPERTENSIVE DRUGS"/CV OR HYPOTENSIVES/CV OR HYPOTENSORS/CV OR HYPERTENSION/CV OR AMLODIPINE/CV OR ATENOLOL/CV OR CANDESARTAN/CV OR CAPTOPRIL/CV OR DOXAZOSIN/CV OR ENALAPRIL/CV OR ENALAPRILAT/CV OR FELODIPINE/CV OR HYDRALAZINE/CV OR HYDROCHLOROTHIAZIDE/CV OR IRBESARTAN/CV OR ISRADIPINE/CV OR LISINOPRIL/CV OR LOSARTAN/CV OR NISOLDIPINE/CV OR NITRENDIPINE/CV OR PERINDOPRIL/CV OR QUINAPRIL/CV OR RAMIPRIL/CV OR VALSARTAN/CV)
 L7 25281 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ANTIHYPERTENSIVE AGENT"/CV OR ANTIHYPERTENSIVES/CV)
 L8 109214 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 OR L7 OR (?HYPERTEN? OR HBP OR HIGH(W) (BLOOD OR BLD) (W) PRESSURE)
 L24 201 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
 L25 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L8

=>

=>

=> d ibib abs hitstr l25 1-3

L25 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:694006 HCAPLUS
 DOCUMENT NUMBER: 140:93082
 TITLE: Effects of niacin-bound chromium, Maitake mushroom fraction SX and (-)-hydroxycitric acid on the metabolic syndrome in aged diabetic Zucker fatty rats
 AUTHOR(S): Talpur, Nadeem; Echard, Bobby W.; Yasmin, Taharat; Bagchi, Debasis; Preuss, Harry G.
 CORPORATE SOURCE: Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC, USA

SOURCE: Molecular and Cellular Biochemistry (2003), 252(1&2), 369-377
 CODEN: MCBIB8; ISSN: 0300-8177
 PUBLISHER: Kluwer Academic Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Previous studies have demonstrated that niacin-bound chromium (NBC), Maitake mushroom, and (-)-hydroxycitric acid (HCA-SX) can ameliorate **hypertension**, dyslipidemia, and diabetes mellitus. They may be useful in body weight (BW) management. We used aged diabetic Zucker fatty rats (ZFR, 70-75 wk old) to determine whether NBC, fraction SX of Maitake mushroom (MSX), and 60% (-)-hydroxycitric acid (HCA-SX) from Garcinia cambogia, alone or in combination, can affect the metabolic syndrome X. The metabolic syndrome X is a concurrence of disturbed glucose and insulin metabolism, overweight, abdominal fat distribution, mild dyslipidemia, and **hypertension**, all of which are associated with subsequent development of type 2 diabetes mellitus and cardiovascular disease. Four groups of 8 ZFR were gavaged daily with the 3 different supplements. For the initial 3 wk, the control ZFR received only water, the second group received NBC with 40 µg elemental Cr/day, the third group MSX at 100 mg/day, and the fourth group HCA-SX at 200 mg/day. During weeks 4-6, the doses in each treatment were doubled. The control rats lost each .apprx.50 g BW over 6 wk of treatment, which is characteristic of these animals in declining health. The 8 ZFR receiving NBC lost each .apprx.9 g BW, while rats fed MSX lost each 16 g BW. ZFR fed HCA-SX simulated the pattern in the control group, as they lost each .apprx.46 g BW. The wide individual variations resulted in a lack of statistical significance among the groups. Nevertheless, 75% ZFR in the control group lost >50 g BW over 6 wk, whereas none of the ZFR fed NBC, 25% ZFR fed MSX, and 57% ZFR fed HCA-SX lost >50 g BW over 6 wk. ZFR in all 3 treatment groups had lower blood pressures compared to controls and this effect seemed to be dose related. The general trend was for renal and liver blood parameters, hepatic and renal lipid peroxidn., and DNA fragmentation to improve due to the supplementation with these natural products. Combination treatment with the 3 supplements led to lower systolic blood pressure and maintenance of BW compared to controls. Elderly diabetics and even aging individuals might benefit from similar dietary regimen.


IT 27750-10-3, (-)-Hydroxycitric acid

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (dietary niacin-bound chromium, Maitake mushroom fraction SX and
 (-)-hydroxycitric acid effects on metabolic syndrome in aged diabetic
 Zucker fatty rats)

RN 27750-10-3 HCAPLUS

CN D-erythro-Pentanic acid, 3-C-carboxy-2-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:851796 HCAPLUS

DOCUMENT NUMBER: 135:366751

TITLE: Methods and pharmaceutical preparations for

INVENTOR(S): normalizing blood pressure with (-)-hydroxycitric acid
 PATENT ASSIGNEE(S): Clouatre, Dallas L.; Dunn, James M.
 SOURCE: USA
 U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001044469	A1	20011122	US 2001-781491	20010213
PRIORITY APPLN. INFO.:			US 2000-181285P	P 20000209

AB A method whereby the blood pressure metabolism in an individual showing evidence of dysregulation is improved when that person receives an appropriate oral administration of (-)-hydroxycitric acid (I). The potassium salt of I is a preferred form of the compound, followed by the sodium salt, then by the amide and other derivs. of the acid. The regulation of blood pressure levels over any given period of time may be improved with a controlled release form of I. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore regulate the use of the compound as a hypotensive agent. Oral administration of 3-4 g of potassium salt of I per day in two divided doses in extremely obese patients normalized the blood pressure along with decrease of blood glucose level.

IT 27750-10-3, (-)-Hydroxycitric acid 27750-10-3D,
 (-)-Hydroxycitric acid, alkaline earth metal salts
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods and pharmaceutical preps. for normalizing blood pressure with hydroxycitric acid salts)


RN 27750-10-3 HCAPLUS
 CN D-erythro-Pentamic acid, 3-C-carboxy-2-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 27750-10-3 HCAPLUS
 CN D-erythro-Pentamic acid, 3-C-carboxy-2-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



DOCUMENT NUMBER: 127:351178
 TITLE: Dietary composition containing chitosan, Garcinia cambogia hydroxycitrate, and organic chromium
 INVENTOR(S): Littera, Renato
 PATENT ASSIGNEE(S): SIRC S.P.A. Natural & Dietetic Foods, Italy
 SOURCE: Eur. Pat. Appl., 6 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 803202	A2	19971029	EP 1997-830189	19970424
EP 803202	A3	19980429		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:

IT 1996-RM279

A 19960426

AB The use of prepn. based on the combination of chitosan with organic chromium and Garcinia cambogia hydroxycitrate as dietary products for the treatment of obesity having hypocholesteremic and sugar absorption reducing activity is disclosed. The proposed combination of chitosan with organic chromium and Garcinia cambogia hydroxycitrate is formulated on the base of the effects that the above three components have on the glucid metabolism. Such effects tends particularly to decrease the values of cholesterolemia and triglycerides in case they are too high. The integrator of the invention can be administered by mouth in the usual dose unit both as capsules and tablets and is efficacious as diet integrator in the weight reducing programs aiming at calorie restrictions in obese subjects, in the treatment of **hypertension**, and as hypocholesteremic product.

IT 27750-10-3, Hydroxycitric acid


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dietary composition containing chitosan, Garcinia cambogia hydroxycitrate, and organic chromium)

RN 27750-10-3 HCAPLUS

CN D-erythro-Pentanic acid, 3-C-carboxy-2-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=> □

=> d stat que

L2 2 SEA FILE=REGISTRY ABB=ON PLU=ON "HYDROXYCITRIC ACID"/CN
 L6 78601 SEA FILE=HCAPLUS ABB=ON PLU=ON (ANTIHYPERTENSIVES/CV OR ANTIHYPERTENSIVE/CV OR "ANTIHYPERTENSIVE AGENT"/CV OR "ANTIHYPER TENSIVE AGENTS"/CV OR "ANTIHYPERTENSIVE DRUGS"/CV OR HYPOTENSI VES/CV OR HYPOTENSORS/CV OR HYPERTENSION/CV OR AMLODIPINE/CV OR ATENOLOL/CV OR CANDESARTAN/CV OR CAPTOPRIL/CV OR DOXAZOSIN/C V OR ENALAPRIL/CV OR ENALAPRILAT/CV OR FELODIPINE/CV OR

HYDRALAZINE/CV OR HYDROCHLOROTHIAZIDE/CV OR IRBESARTAN/CV OR
 ISRADIPINE/CV OR LISINOPRIL/CV OR LOSARTAN/CV OR NISOLDIPINE/CV
 OR NITRENDIPINE/CV OR PERINDOPRIL/CV OR QUINAPRIL/CV OR
 RAMIPRIL/CV OR VALSARTAN/CV)

L7 25281 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ANTIHYPERTENSIVE AGENT"/CV
 OR ANTIHYPERTENSIVES/CV)

L8 109214 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 OR L7 OR (?HYPERTEN? OR
 HBP OR HIGH(W) (BLOOD OR BLD) (W) PRESSURE)

L24 201 SEA FILE=HCAPLUS ABB=ON PLU=ON L2

L25 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L8

L26 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND (BLOOD OR BLD) (W) PRESS
 URE

L27 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L26 NOT L25

=>

=>

=> d ibib abs hitstr

L27 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:593955 HCAPLUS

DOCUMENT NUMBER: 139:337370

TITLE: The effect of a potential antiobesity-supplement on
 weight loss and visceral fat accumulation in
 overweight women

AUTHOR(S): Cha, Bo Ram; Chae, Jey Sook; Lee, Jong Ho; Jang, Yang
 Soo; Lee, Jin Hee; Son, Jong Wook

CORPORATE SOURCE: Department of Food and Nutrition, Yonsei University,
 Seoul, 120-749, S. Korea

SOURCE: Hanguk Yongyang Hakhoechi (2003), 36(5), 483-490
 CODEN: HYHJA3; ISSN: 0367-6463

PUBLISHER: Korean Nutrition Society

DOCUMENT TYPE: Journal

LANGUAGE: Korean

AB The purpose of this study was to evaluate the combined effects of
 chitosan, hydroxycitrate and L-carnitine mixture as a potential antiobesity
 supplement in overweight women. Pre-menopausal healthy females who were
 overweight (percent ideal body weight > 110) were included in this study.
 Forty-nine subjects randomly received a placebo (n = 25) or
 antiobesity-supplement (n = 24), which was a mixture of chitosan,
 hydroxycitrate, and L-carnitine. Before and after the eight-week exptl.
 period, anthropometric parameters, blood components and computerized
 tomog. were measured. At baseline, the two groups were well matched in
 terms of age, body mass index and lipid profile. After the eight weeks of
 potential antiobesity supplementation, the subjects' body fat percent had
 decreased significantly ($p < 0.001$) by 5.6% (39.1 ± 1 vs $36.9 \pm 1\%$)
 while lean body mass increased ($p < 0.01$). Visceral fat area at the L4
 vertebra decreased significantly ($p < 0.01$) by 8.6% in the supplemented
 group and the total fat area at the L4 vertebra showed a tendency to
 decrease ($p = 0.051$) by 2.4%. Also, in the group given the
 antiobesity-supplement rather than the placebo, the fasting triglyceride
 level decreased significantly ($p < 0.05$) by 10.0%. In addition, serum total
 cholesterol levels in the antiobesity-supplement group showed a tendency
 to decrease ($p=0.159$) by 2.7% (194 ± 6 vs 189 ± 6 mg/dL). No side
 effects were found in either group during the intervention. In
 conclusion, the present study demonstrated that taking a mixture of
 chitosan, hydroxy-citrate, and L-carnitine as a potential antiobesity
 supplement for eight weeks produced advantageous changes in the weight and
 visceral fat accumulation of overweight women without any side effects.

IT 27750-10-3, Hydroxy citric acid


RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antiobesity-supplement effect on weight loss and visceral fat accumulation in overweight women)

RN 27750-10-3 HCAPLUS

CN D-erythro-Pentartic acid, 3-C-carboxy-2-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=> L

=> d stat que

L2 2 SEA FILE=REGISTRY ABB=ON PLU=ON "HYDROXYCITRIC ACID"/CN
 L6 78601 SEA FILE=HCAPLUS ABB=ON PLU=ON (ANTIHYPERTENSIVES/CV OR ANTIHYPERTENSIVE/CV OR "ANTIHYPERTENSIVE AGENT"/CV OR "ANTIHYPERRTENSIVE AGENTS"/CV OR "ANTIHYPERTENSIVE DRUGS"/CV OR HYPOTENSIVES/CV OR HYPOTENSORS/CV OR HYPERTENSION/CV OR AMLODIPINE/CV OR ATENOLOL/CV OR CANDESARTAN/CV OR CAPTOPRIL/CV OR DOXAZOSIN/CV OR ENALAPRIL/CV OR ENALAPRILAT/CV OR FELODIPINE/CV OR HYDRALAZINE/CV OR HYDROCHLOROTHIAZIDE/CV OR IRBESARTAN/CV OR ISRADIPINE/CV OR LISINOPRIL/CV OR LOSARTAN/CV OR NISOLDIPINE/CV OR NITRENDIPINE/CV OR PERINDOPRIL/CV OR QUINAPRIL/CV OR RAMIPRIL/CV OR VALSARTAN/CV)
 L7 25281 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ANTIHYPERTENSIVE AGENT"/CV OR ANTIHYPERTENSIVES/CV)
 L8 109214 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 OR L7 OR (?HYPERTEN? OR HBP OR HIGH(W) (BLOOD OR BLD) (W) PRESSURE)
 L24 201 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
 L25 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L8
 L26 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND (BLOOD OR BLD) (W) PRESSURE
 L27 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L26 NOT L25
 L28 318474 SEA FILE=HCAPLUS ABB=ON PLU=ON ("BLOOD PRESSURE"/CV OR "ARTERIAL BLOOD PRESSURE"/CV OR BARORECEPTORS/CV OR BLOOD/CV OR "BLOOD VESSEL"/CV OR CIRCULATION/CV OR HYPERTENSION/CV OR HYPOTENSION/CV)
 L29 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L28
 L30 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L29 NOT (L25 OR L27)

=> d ibib abs l30 1-5

L30 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:877940 HCAPLUS
 DOCUMENT NUMBER: 141:370229
 TITLE: Controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compositions
 INVENTOR(S): Gupta, Shyam K.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 9 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004208902	A1	20041021	US 2003-418495	20030418
PRIORITY APPLN. INFO.:			US 2003-418495	20030418

AB The present invention discloses the utilization of zeolites for controlled-release of cosmetic and pharmaceutical compns. by nano-diffusion technol. The treatment and protection of skin surface requires that certain compns. be delivered to the skin surface and allowed to remain on the skin surface for as long as possible before such ingredients are absorbed into deeper layers of skin and carried into the bloodstream. Zeolites do not absorb into the skin, which is useful for topical delivery of cosmetic and pharmaceutical compns., for example antiaging, anti-wrinkle, antioxidants, skin whitening, acne treatment, rosacea treatment, sun screens, UV blocks, anesthetics, skin soothers, anti-irritants, anti-inflammatory agents, vitamins, hormones, and such that are electronically attached to the outer surfaces of such zeolites and are released to the outer surface of skin by a diffusion-controlled thermodyn. process. An anhydrous face mask controlled-release antiaging composition with heat-releasing effect. comprises magnesium sulfate (anhydrous) 30.0, glycerin 49.0, sodium potassium aluminosilicate (Zeolite A3) 20.0, an antiaging composition (an equal weight mixture of tetrahydrocurcumin, niacinamide lactate, copper ATP complex, glutathione, and carnosine)1.0%.

L30 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:681187 HCAPLUS
 DOCUMENT NUMBER: 141:194959
 TITLE: Skin firming anti-aging cosmetic compositions
 INVENTOR(S): Gupta, Shyam K.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004161435	A1	20040819	US 2003-248753	20030214
PRIORITY APPLN. INFO.:			US 2003-248753	20030214

AB Cosmetic mask compns. suitable for face, neck, chin or body applications are disclosed. These compns. synergistically combine at least 1 skin beneficial cosmetic or pharmaceutical composition with at least one composition to promote excess fat reduction, cellulite control, or muscle toning benefits. The mask composition also contains at least one binder composition that binds with other beneficial ingredients by electrostatic, atomic, or ionic charges to synergistically enhance their topical site-specific benefits. These mask compns. are suitable for a variety of delivery system methods that include, e.g., peel-off mask, leave-in mask, moisturizing mask, and exfoliating mask. Thua, a facial mask composition contained chitosan 5.0, lactic acid 5.0, glycerin 18.0, water 65.8, hydroxycitric acid 5.0, niacinamide 0.5, glutathione, and preservatives 0.5%.

L30 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:609740 HCAPLUS
 DOCUMENT NUMBER: 141:162091
 TITLE: Topical nutraceutical compositions with selective body slimming and tone firming antiaging benefits
 INVENTOR(S): Gupta, Shyam K.
 PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004146539	A1	20040729	US 2003-248508	20030124
PRIORITY APPLN. INFO.:			US 2003-248508	20030124

AB Cosmetic or topical pharmaceutical compns. are described for external body part or organ slimming, firming, cellulite reduction, fat-reduction, and obesity control benefits that are in synergistic combination with benefits for the treatment of skin aging, skin wrinkles reduction, skin exfoliating, treatment of acne, treatment of rosacea, age-spots reduction, skin surface whitening, skin surface brightening striae distensae (stretch marks) reduction, treatment of pimples, treatment of skin infections and lesions, spider veins reduction, blood microcirculation (venous insufficiency) improvement, UVA/UVB protection of skin, and skin redness reduction. These compns. thus provide multiple combinations of skin and external body part or organ enhancement benefits that can be selective and specific for external body parts and organs such as face, chin, cheeks, arms, "love handles" in abdomen area, eye lids and eye zone, neck, breasts, thighs, and hips. For example, a chitosan facial mask composition for the reduction of wrinkles and excess fat on cheeks and eyelids contained chitosan 5%, lactic acid 5%, glycerin 18%, water 65.8%, hydroxycitric acid 5%, niacinamide 0.5%, glutathione 0.2%, and preservatives 0.5%. First three components were mixed into a paste, other components were mixed sep. into a clear solution, and the paste and the solution were combined to obtain a clear gel product. The gel is applied on the face and neck and left for 10 to 30 min, then rinsed off.

L30 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:716922 HCAPLUS
 DOCUMENT NUMBER: 137:216324
 TITLE: Nutritional supplement for modulating nutrient partitioning in human to increase oxidation of fat and storage of glycogen
 INVENTOR(S): McCleary, Larry
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 7 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132219	A1	20020919	US 2000-749584	20001228
US 6579866	B2	20030617		
US 2004043013	A1	20040304	US 2003-462958	20030617
PRIORITY APPLN. INFO.:			US 2000-749584	A2 20001228

AB A nutritional supplement composition for modulating nutrient partitioning in a human so as to increase oxidation of fat and promote increased storage of glycogen is composed of hydroxycitric acid, carnitine, biotin, a gluconeogenic substrate, and, optionally, one or more of chromium, conjugated linoleic acid, coenzyme Q10, eicosapentaenoic acid, pyridoxine, alpha-lipoic acid, magnesium, and gymnema sylvestre. A method for modulating nutrient partitioning in a human involves orally or parenterally administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of

time. Preferably, the method further involves having the human follow a specific dietary regimen wherein the glycemic index is less than 60 and the daily calorie consumption from carbohydrates is less than about 50% and the daily calorie consumption from protein is at least about 20%. Optionally, the method further involves an exercise program, a stress reduction program and/or a blood donation program.

L30 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:568067 HCAPLUS

DOCUMENT NUMBER: 132:121909

TITLE: (-)-hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state

AUTHOR(S): Kriketos, A. D.; Thompson, H. R.; Greene, H.; Hill, J. O.

CORPORATE SOURCE: Center for Human Nutrition, University of Colorado Health Sciences Center, Denver, CO, 80262, USA

SOURCE: International Journal of Obesity (1999), 23(8), 867-873

CODEN: IJOBDP; ISSN: 0307-0565

PUBLISHER: Stockton Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In a fasted state and following 3 d of (-)-hydroxycitric acid (HCA) (promoted as a weight loss agent) treatment, RQ of sedentary adult men was not significantly lowered during rest (Protocol A) nor during exercise (Protocol B) compared with placebo treatment. Treatment with (HCA) did not affect energy expenditure, either during rest or during moderately intense exercise. Furthermore, the blood substrates measured were not significantly different between treatment groups under the fasting conditions of this study. These results do not support the hypothesis that (-)-HCA alters the short-term rate of fat oxidation in the fasting state during rest or moderate exercise, with doses likely to be achieved in humans while subjects maintain a typical Western diet (approx 30-35% total calories as fat).

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> □

=> d stat que

L2 2 SEA FILE=REGISTRY ABB=ON PLU=ON "HYDROXYCITRIC ACID"/CN
 L6 78601 SEA FILE=HCAPLUS ABB=ON PLU=ON (ANTIHYPERTENSIVES/CV OR ANTIHYPERTENSIVE/CV OR "ANTIHYPERTENSIVE AGENT"/CV OR "ANTIHYPERTENSIVE AGENTS"/CV OR "ANTIHYPERTENSIVE DRUGS"/CV OR HYPOTENSIVES/CV OR HYPOTENSORS/CV OR HYPERTENSION/CV OR AMLODIPINE/CV OR ATENOLOL/CV OR CANDESARTAN/CV OR CAPTOPRIL/CV OR DOXAZOSIN/CV OR ENALAPRIL/CV OR ENALAPRILAT/CV OR FELODIPINE/CV OR HYDRALAZINE/CV OR HYDROCHLOROTHIAZIDE/CV OR IRBESARTAN/CV OR ISRADIPINE/CV OR LISINOPRIL/CV OR LOSARTAN/CV OR NISOLDIPINE/CV OR NITRENDIPINE/CV OR PERINDOPRIL/CV OR QUINAPRIL/CV OR RAMIPRIL/CV OR VALSARTAN/CV)
 L7 25281 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ANTIHYPERTENSIVE AGENT"/CV OR ANTIHYPERTENSIVES/CV)
 L8 109214 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 OR L7 OR (?HYPERTEN? OR HBP OR HIGH(W) (BLOOD OR BLD) (W) PRESSURE)
 L24 201 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
 L25 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L8
 L26 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND (BLOOD OR BLD) (W) PRESSURE
 L27 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L26 NOT L25

L28 318474 SEA FILE=HCAPLUS ABB=ON PLU=ON ("BLOOD PRESSURE"/CV OR
 "ARTERIAL BLOOD PRESSURE"/CV OR BARORECEPTORS/CV OR BLOOD/CV
 OR "BLOOD VESSEL"/CV OR CIRCULATION/CV OR HYPERTENSION/CV OR
 HYPOTENSION/CV)
 L29 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L24 AND L28
 L30 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L29 NOT (L25 OR L27)
 L37 2 SEA FILE=REGISTRY ABB=ON PLU=ON ("GARCINIA ACID"/CN OR
 "GARCINIA ACID DIETHYL ESTER"/CN)
 L38 SEL PLU=ON L37 1- CHEM : 10 TERMS
 L39 244 SEA FILE=HCAPLUS ABB=ON PLU=ON L38
 L40 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L39(L) (L8 OR L28)
 L41 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L40 NOT (L25 OR L27 OR L30)

=>

=>

=> d ibib abs hitrn l41 1

L41 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1939:52304 HCAPLUS

DOCUMENT NUMBER: 33:52304

ORIGINAL REFERENCE NO.: 33:7491c-g

TITLE: Hibiscus "flowers," a drug used in the preparation of
 food and drink, its principal component a new acid of
 fruit acid character (hibiscus acid)

AUTHOR(S): Griebel, C.

SOURCE: Zeitschrift fuer Untersuchung der Lebensmittel (1939),
 77, 561-71

CODEN: ZULEA8; ISSN: 0373-0174

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB The botanical characteristics of the fruit calyx (I) of Hibiscus
 sabdariffa L. are described. Trade and com. preps. of I are called
 karkade, Jericho-rose, roselle and red sorrel. They are recommended for
 heart and nerve diseases, **high blood pressure**
 , calcified arteries, etc. A new acid was obtained from I by extraction with
 95% alc., precipitating with Pb acetate, filtering, removing the Pb from the
 precipitate
 with H₂S and crystallizing The Pb salt crystallized into thin prismatic crystals
 unlike those of tartaric, malic or citric acids. The acid sublimates to
 needle-like crystals similar to those of citric acid. Reactions of
 Denig`es (Bulletin society pharm. Bordeaux 1898) and Stahre (Ber. 17,
 2687(1884); 23, 831(1890)) for citric acid were, resp., pos. and neg.
 Unlike malic or citric acids it reduces ammoniacal AgNO₃ solution The
 reaction of Celsi (C. A. 20, 3666) for malic acid was neg. The acid is
 very soluble in water and alc., slightly soluble in ether a 5% aqueous solution has a
 sp. rotation of +11°, m. 181-3°, the p-nitrobenzyl ester
 decomposed 172°, the phenacyl ester decomposed 177°, the quinine
 salt m. 227-8°, analyses of the Pb salt and phenacyl ester
 indicated the formula C₆H₆O₇ for the acid and other tests indicated 2
 carboxyl groups per mol. The tests suggest that it is a lactone of
hydroxycitric acid with 2 asym. C atoms (*):
 HO₂CCH₂C(OH).CO.O.CHCO₂H. The acid was named hibiscus acid.


=> => d stat que l42

L42 1 SEA FILE=REGISTRY ABB=ON PLU=ON 27750-11-4/RN

=> d ide can l42 1

L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 27750-11-4 REGISTRY
 CN D-threo-Pentamic acid, 3-C-carboxy-2-deoxy- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,2,3-Propanetricarboxylic acid, 1,2-dihydroxy-, (1S,2R)- (8CI)
 OTHER NAMES:
 CN (+)-allo-Hydroxycitric acid
 CN (+)-Allohydroxycitric acid
 CN allo-2-Hydroxycitric acid
 CN allo-Hydroxycitric acid
 CN Citric acid, 2-hydroxy-, allo-
 CN Hibiscus acid
 FS STEREOSEARCH
 DR 23053-06-7
 MF C6 H8 O8
 CI COM
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT,
 NAPRALERT, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
 study); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 PROC (Process); PRP (Properties); RACT (Reactant or reagent); NORL (No
 role in record)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:325781
 REFERENCE 2: 136:36817
 REFERENCE 3: 133:271625
 REFERENCE 4: 122:169713
 REFERENCE 5: 114:77529
 REFERENCE 6: 100:134543
 REFERENCE 7: 98:211981

REFERENCE 8: 97:68369

REFERENCE 9: 94:171129

REFERENCE 10: 90:199530

=>

? SHOW FILES

File 155:MEDLINE(R) 1951-2004/Nov W3
 (c) format only 2004 The Dialog Corp.
 File 5:Biosis Previews(R) 1969-2004/Nov W2
 (c) 2004 BIOSIS
 File 351:Derwent WPI 1963-2004/UD,UM &UP=200475
 (c) 2004 Thomson Derwent

?

?

? DS

Set	Items	Description
S1	1016	((ALLOHYDROXYCITRIC OR HYDROXYCITRIC OR HIBISCUS) (W)ACID)OR (ALLOHYDROXYCITRATE OR HYDROXYCITRATE OR (ALLOHYDROXY OR HYD- ROXY) (2N) (CITRIC OR CITRATE))
S2	3	(PROPANETRICARBOXYLIC (5N)DIHYDROXY? OR (THREO (W) PENTAR?) (S- CARBOXY? (2N) (2 (W)DEOXY))
S3	8	(S1 OR S2) (S) (HYPERTEN? OR ANTIHYPERTEN? OR (BLD OR BLOOD) - (W)PRESSURE)
S4	7	RD (unique items)

?

?

? T S4/3 AB KWIC/1-7

4/ABKWIC/1 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2004 The Dialog Corp. All rts. reserv.

17247936 PMID: 15544444

A perspective on the current strategies for the treatment of obesity.

Joyal Steven V

Global Clinical Research, Pharmaceutical Research Institute,
 Bristol-Myers Squibb, Princeton, New Jersey, USA. steven.joyal@bms.com.

Current drug targets. CNS and neurological disorders (Netherlands) Oct
 2004, 3 (5) p341-56, ISSN 1568-007X Journal Code: 101151150

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Data Review

The prevalence in obesity has increased dramatically over the past 30 years, more than double in the United States alone. Obesity is associated with an increased risk for type 2 diabetes mellitus, dyslipidemia, hypertension, biliary disease, obstructive sleep apnea, and certain types of cancer. The pathophysiology of obesity is complex, involving behavioral, environmental, and genetic factors. Current treatment options include behavior modification and lifestyle changes which incorporate weight-reducing diets and physical activity, FDA approved long-term anti-obesity pharmacological agents sibutramine and orlistat, non-FDA approved over-the-counter (OTC) supplements and nutraceuticals, and, when appropriate, bariatric surgery. Without adequate prevention and treatment of obesity, government agencies have suggested that the direct and indirect costs associated with obesity may overwhelm the healthcare system. This brief review explores the current data available on treatments for the obese patient including the relative merits of different types of macronutrient composition (e.g., low carbohydrate vs. high carbohydrate diets) of weight-reducing diets, the value of resistance/ strength training in physical activity programs designed for the obese patient, the safety and efficacy associated with OTC supplements and nutraceuticals for weight reduction (e.g., Ephedra, conjugated linoleic acid (CLA), Garcinia cambogia/ hydroxycitric acid (HCA), chromium, pyruvate), the safety and efficacy of FDA-approved long-term obesity treatments sibutramine and orlistat, and bariatric surgery.

... supplements and nutraceuticals for weight reduction (e.g., Ephedra, conjugated linoleic acid (CLA), Garcinia cambogia/ **hydroxycitric acid** (HCA), chromium, pyruvate), the safety and efficacy of FDA-approved long-term obesity treatments sibutramine...

4/ABKWIC/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

16261453 PMID: 14577612

Effects of niacin-bound chromium, Maitake mushroom fraction SX and (-)-hydroxycitric acid on the metabolic syndrome in aged diabetic Zucker fatty rats.

Talpur Nadeem; Echard Bobby W; Yasmin Taharat; Bagchi Debasis; Preuss Harry G

Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20057, USA.

Molecular and cellular biochemistry (Netherlands) Oct 2003, 252 (1-2) p369-77, ISSN 0300-8177 Journal Code: 0364456

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Previous studies in our laboratories have demonstrated that niacin-bound chromium (NBC), Maitake mushroom and (-)-hydroxycitric acid (HCA-SX) can ameliorate **hypertension**, dyslipidemias and diabetes mellitus, and therefore may be useful in weight management. In the present study, we used aged, diabetic Zucker fatty rats (ZFR) (70-75 weeks) in order to determine whether NBC, fraction SX of Maitake mushroom (MSX) and 60% (-)-**hydroxycitric acid** (HCA-SX) from Garcinia cambogia, alone or in combination, can affect certain aspects of the metabolic syndrome. Syndrome X or metabolic syndrome has been described as a concurrence of disturbed glucose and insulin metabolism, overweight and abdominal fat distribution, mild dyslipidemia, and **hypertension**, which are associated with subsequent development of type 2 diabetes mellitus and cardiovascular disease. Four groups of eight ZFR were gavaged daily with different supplements. For the initial three weeks, the control group of ZFR received only water, the second group received NBC 40 mcg elemental chromium/day, the third group received MSX 100 mg/day and the last group received HCA-SX 200 mg/day. During weeks 4-6, the doses of each treatment were doubled. The control animals lost approximately 50 g body weight (BW) per rat over 6 weeks of treatment, which is characteristic of these animals in declining health. In contrast, eight ZFR receiving NBC lost approximately 9 g BW per rat, while rats consuming MSX lost 16 g BW per rat. However, ZFR receiving HCA-SX simulated the pattern in the control group because these animals lost approximately 46 g BW per rat. The wide individual variations resulted in a lack of statistical significance among groups. Nevertheless, 75% of the ZFR in the control group lost more than 50 g BW over the 6 weeks duration, whereas none of the ZFR receiving NBC, 25% of the ZFR receiving MSX and 57% of the ZFR receiving HCA-SX lost over 50 g BW over the 6 weeks of the study. ZFR in all 3 treatment groups showed significantly lower blood pressures as compared to control, which seemed to be dose related. The general trend was for renal and liver blood parameters, hepatic and renal lipid peroxidation and DNA fragmentation to improve due to the supplementation of these natural products. Treatment of animals with a combination of these three novel supplements resulted in a lower SBP and maintenance of BW compared to control animals. These results demonstrate that elderly diabetics and even aging individuals might benefit from a similar regimen.

... demonstrated that niacin-bound chromium (NBC), Maitake mushroom and (-)-hydroxycitric acid (HCA-SX) can ameliorate **hypertension**, dyslipidemias and diabetes mellitus, and therefore may be useful in weight management. In the present...

... weeks) in order to determine whether NBC, fraction SX of Maitake mushroom (MSX) and 60% (-)-**hydroxycitric acid** (HCA-SX) from *Garcinia cambogia*, alone or in combination, can affect certain aspects of the...

... concurrence of disturbed glucose and insulin metabolism, overweight and abdominal fat distribution, mild dyslipidemia, and **hypertension**, which are associated with subsequent development of type 2 diabetes mellitus and cardiovascular disease. Four...

4/ABKWIC/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07772154 PMID: 3368856

[Treatment of patients with food toxoinfections in middle and old age]
Lechenie bol'nykh s pishchevymi toksikoinfektsiiami v pozhilom i starcheskom vozraste.

Bro dov L E; Maleev V V; Chekalina K I; Bogin I B

Terapevticheskii arkhiv (USSR) 1988, 60 (2) p132-4, ISSN 0040-3660
Journal Code: 2984818R

Document type: Journal Article ; English Abstract

Languages: RUSSIAN

Main Citation Owner: NLM

Record type: Completed

Altogether 320 elderly and old-aged patients with alimentary toxoinfections suffering from essential **hypertension** (65.9%), coronary heart disease (39.3%), atherosclerosis (29.3%) were observed. A severe course of toxoinfection was noted in 5.9% of the patients, an average severe course in 94.1%. The patients received intravenously the "quartasol" solution in full volume (25.7%) or the ORS solution with sodium **hydroxycitrate** per os (74.3%). Therapeutic efficacy was high. **Antihypertensive** therapy and antianginal drugs were simultaneously administered. Neither complications nor side effects were observed during therapy of the elderly and old-aged patients with alimentary toxoinfections. In addition to the above therapy all the patients received sparing diet and enzyme preparations.

Altogether 320 elderly and old-aged patients with alimentary toxoinfections suffering from essential **hypertension** (65.9%), coronary heart disease (39.3%), atherosclerosis (29.3%) were observed. A severe course...

...intravenously the "quartasol" solution in full volume (25.7%) or the ORS solution with sodium **hydroxycitrate** per os (74.3%). Therapeutic efficacy was high. **Antihypertensive** therapy and antianginal drugs were simultaneously administered. Neither complications nor side effects were observed during...

4/ABKWIC/4 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0007183249 BIOSIS NO.: 199089101140

EVIDENCE OF A SLOW-TO-FAST FIBER TYPE TRANSITION IN SKELETAL MUSCLE FROM

SPONTANEOUSLY HYPERTENSIVE RATS

AUTHOR: BACHIR-LAMRINI L B (Reprint); SEMPORE B; MAYET M-H; FAVIER R J
AUTHOR ADDRESS: URA 1341 CNRS, LABORATOIRE DE PHYSIOLOGIE A, 8 AVE
ROCKEFELLER, 69373 LYON CEDEX 08, FRANCE**FRANCE
JOURNAL: American Journal of Physiology 258 (2 PART 2): pR352-R357 1990
ISSN: 0002-9513
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: The histochemical, biochemical, and electrophysiological properties of selected muscles were evaluated in spontaneously hypertensive rats (SHR) and compared with their normotensive. Wistar-Kyoto (WKY) counterparts. As early as 4 wk of age, slow muscles (soleus) of SHR displayed a significant alteration in fiber type distribution with a decrease of slow-twitch fibers (from 64 to 53%) and a simultaneous increase of type IIA-fibers (from 19 to 39%). In addition, soleus from young SHR had a significant enhancement of both oxidative (citrate synthase, 3-hydroxy-acyl-CoA dehydrogenase) and glycolytic [lactate dehydrogenase (LDH)] capacities, which could be partly related to a capillary rarefaction. During development (from the 4th to the 12-14th wk), in the soleus muscle the histochemical differences between SHR and WKY were amplified, whereas most of the enzymatic differences between strains were abolished, except for a significantly higher LDH activity. These histochemical changes had only marginal repercussions on soleus electrophysiological properties. SHR animals had a significantly higher basal metabolic rate, which could not be accounted for by elevation of thyroid hormones. The origin of the slow-to-fast fiber type transition in slow muscle remains unclear but could be related to the increased level of plasma catecholamines in SHR. Indeed, chronic treatment of rats with a β 2-receptor agonist has been reported to cause slow-to-fast muscle fiber transition [R. J. Zeman, R. L. Ludemann, T. G. Easton, and J. D. Etlinger. Am. J. Physiol. 245 (Endocrinol. Metabolism 17): E726, 1988].

...ABSTRACT: to 39%). In addition, soleus from young SHR had a significant enhancement of both oxidative (citrate synthase, 3-hydroxy-acyl-CoA dehydrogenase) and glycolytic [lactate dehydrogenase (LDH)] capacities, which could be partly related to...

4/ABKWIC/5 (Item 1 from file: 351)
DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts.reserv.

015536019

WPI Acc No: 2003-598169/200356
Related WPI Acc No: 2002-750629
XRAM Acc No: C03-162246

Pharmaceutical composition, useful for the promotion of healthy body weight, and to reduce the risk of obesity related ailments e.g.

hypertension, type II diabetes or arthritis, comprises
hydroxycitric acid

Patent Assignee: INTERHEALTH NUTRACEUTICALS (INTE-N); INTERHEALTH NUTRACEUTICALS INC (INTE-N); BAGCHI D (BAGC-I); PREUSS H G (PREU-I)

Inventor: BAGCHI D; PREUSS H G

Number of Countries: 101 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200353454	A1	20030703	WO 2002US41171	A	20021220	200356 B
US 20040014692	A1	20040122	US 2001343473	P	20011220	200407

			US 2002325675	A	20021220	
AU 2002364213	A1	20030709	AU 2002364213	A	20021220	200428
EP 1461051	A1	20040929	EP 2002799288	A	20021220	200463
			WO 2002US41171	A	20021220	

Priority Applications (No Type Date): US 2001343473 P 20011220; US 2002325675 A 20021220

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

WO 200353454	A1	E	17	A61K-033/24	
--------------	----	---	----	-------------	--

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

Designated States (Regional): AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW

US 20040014692	A1		A61K-031/704	Provisional application	US 2001343473
----------------	----	--	--------------	-------------------------	---------------

AU 2002364213	A1		A61K-033/24	Based on patent	WO 200353454
---------------	----	--	-------------	-----------------	--------------

EP 1461051	A1	E	A61K-033/24	Based on patent	WO 200353454
------------	----	---	-------------	-----------------	--------------

Designated States (Regional): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR

Abstract (Basic): WO 200353454 A1

Abstract (Basic):

NOVELTY - Increase of a serotonin level involves administration of a composition (C1) comprising hydroxycitric acid (HCA).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition (C2) comprising hydroxycitric acid, chromium and gymnemic acid.

ACTIVITY - Antilipemic; Anorectic; Antiarthritic; Hypotensive; Antidiabetic; Cytostatic.

The antilipemic and anorectic activity was evaluated in individuals by administering a placebo (control), a daily dose of Garcinia cambogia extract (4667 mg) (test 1) and a combination of HCA-SX Super CitriMax (RTM; hydroxycitric acid composition) and ChromeMate (RTM; HCA-SX, chromium and gymnemic acid composition) (test 2) in three equally divided doses for 30-60 minutes before breakfast for 8 weeks. The (%) changes obtained for control/test 1/test 2, respectively, were:

- (1) body weight=1.9/5.0/6.5;
- (2) LDL cholesterol=2.8/-13.0/-19.0; and
- (3) food intake reduction=0/11.4/17.2.

MECHANISM OF ACTION - Serotonin release stimulator; Serotonin release uptake inhibitor; Lipogenesis inhibitor; Fat synthesis inhibitor; Obesity gene down regulator.

USE - The composition is useful for reducing excess/maintaining healthy body weight or body mass index. It also serves to suppress appetite and/or lead to a reduction in food intake. Furthermore, the composition is useful for decreasing total cholesterol, LDL cholesterol and/or triglyceride levels (all claimed) and obesity gene level. By the promotion of healthy body weight, obesity associated ailments such as arthritis, hypertension, type II diabetes, elevated cholesterol and cancer can be prevented.

ADVANTAGE - The composition improves physiological factors including serum serotonin level, serum leptin level, fat oxidation, cholesterol level and body mass index. HCA increases serum leptin level, thus down regulating the genetic propensity toward obesity. HCA produces its effect without stimulating the central nervous system. The composition provides enhanced biochemical induction of glycerol kinase, which can serve to enhance two important biochemical functions such as biochemical reduction of triglyceride levels and fat oxidation.

pp; 17 DwgNo 0/0

... of healthy body weight, and to reduce the risk of obesity related ailments e.g. **hypertension**, type II diabetes or arthritis, comprises **hydroxycitric acid**

4/ABKWIC/6 (Item 2 from file: 351)
DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

015121603

WPI Acc No: 2003-182126/200318

XRAM Acc No: C03-047883

Use of (-)-hydroxycitric acid for treating and ameliorating polymorphic metabolic dysfunction

Patent Assignee: CLOUATRE D L (CLOU-I); DUNN J M (DUNN-I)

Inventor: CLOUATRE D L; DUNN J M

Number of Countries: 001 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 6476071	B1	20021105	US 2001850280	A	20010507	200318 B
US 20020193430	A1	20021219	US 2001850280	A	20010507	200318

Priority Applications (No Type Date): US 2001850280 A 20010507

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
US 6476071	B1	16	A01N-037/00		
US 20020193430	A1		A61K-031/366		

Abstract (Basic): US 6476071 B1

Abstract (Basic):

NOVELTY - Treating and ameliorating polymorphic metabolic dysfunction (PMD) involves administration of (-)-hydroxycitric acid (A). PMD is characterized by glucocorticoid metabolism dysregulation. (A) influences the regulation of glucocorticoid metabolism of leptin, resistin or peroxisome proliferator-activated receptor-gamma (PPAR-gamma).

ACTIVITY - Antilipemic; Anorectic.

An open clinical weight loss trial with extremely obese patients was undertaken to gauge the effects of a pouch delivery form of a potassium salt of (-)-**hydroxycitrate** acid (HCA). The patients were enrolled with diabetes and these suspected of suffering from insulin resistance. The patients were administered HCA (3-4 g/day) in 2 doses. The patients experienced good appetite suppression. The average weight loss over the 3 week period for the patients were 3.1 pounds per person. HCA also showed an ability to normalize **blood pressure**.

MECHANISM OF ACTION - PMD regulator; Blood lipid inducer; Weight loss inducer.

USE - For treating and ameliorating polymorphic metabolic dysfunction, elevated glucocorticoid levels, leptin levels and leptin resistance, resistin levels and proliferative-activated receptor-gamma activity (all claimed). Also reduces blood lipids, induces weight loss and decrease appetite.

ADVANTAGE - (A) Influences the regulation of glucocorticoid metabolism of leptin, resistin or peroxisome proliferator-activated receptor-gamma (PPAR-gamma). The regulation of PMD over any given period of time may be improved with a controlled release form of (A).

(A) Has a multitude of metabolic functions and reduces blood lipids, induces weight loss and decrease appetite in both animals and humans.

pp; 16 DwgNo 0/4

Abstract (Basic):

... undertaken to gauge the effects of a pouch delivery form of a potassium salt of (-)-**hydroxycitrate** acid (HCA). The patients were enrolled with diabetes and these suspected of suffering from insulin...

...the patients were 3.1 pounds per person. HCA also showed an ability to normalize **blood pressure**.

4/ABKWIC/7 (Item 3 from file: 351)
DIALOG(R)File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

014245316

WPI Acc No: 2002-066016/200209

XRAM Acc No: C02-019572

Treating or ameliorating **hypertension** or high **blood pressure** involves orally administering (-)-**hydroxycitric acid**

Patent Assignee: CLOUATRE D L (CLOU-I); DUNN J M (DUNN-I)

Inventor: CLOUATRE D L; DUNN J M

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20010044469	A1	20011122	US 2000181285	A	20000209	200209 B
			US 2001781491	A	20010213	

Priority Applications (No Type Date): US 2000181285 P 20000209; US 2001781491 A 20010213

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

US 20010044469 A1 6 A61K-031/194 Provisional application US 2000181285

Abstract (Basic): US 20010044469 A1

Abstract (Basic):

NOVELTY - Treating or ameliorating **hypertension** or high **blood pressure** involves administering orally (-)-**hydroxycitric acid**.

ACTIVITY - Hypotensive; antidiabetic.

Ten-week old male rats were placed on a moderate fat diet (30% of calories) for 60 days. These rats were fed water or potassium **hydroxycitrate** (KHCA) (0.33 mmols/kg) twice daily by gastric intubation. Five animals were used as controls and two different formulas of KHCA were provided to five animals each. At the termination of the trial, the differences between control (5 data points) and active (10 data points) were then analyzed according to student's T test. There was no significant difference between control and the KHCA groups with regard to non-esterified fatty acids (NEFA). Insulin levels in the animals given KHCA was significantly lower than in controls, with a one-tailed P value of 0.0306; in the two-tailed test, P was just short of significance at 0.0612 because of the small number of animals. Corticosterone levels were also very significantly lower in the KHCA groups than in control, with a one-tailed P value of 0.0013 and a two-tailed P value of 0.0026. Both of these factors played a role in the clinical findings of lowered **blood pressure** in **hypertensive** individuals.

MECHANISM OF ACTION - None given in the source material.

USE - For treating or ameliorating hypertension or high blood pressure (claimed); for treating patients suffering from salt-sensitive

hypertension and insulin resistance due to chronic hyperinsulinemia.

ADVANTAGE - The (-)-**hydroxycitric acid** lowers elevated insulin and elevated stress hormone levels (preferably glucocorticoid levels) and thus reduces the elevated **blood pressure** level without any side effects. The treatment provides an improvement in the **blood pressure** metabolism that shows evidence of dysregulation.

pp; 6 DwgNo 0/0

Treating or ameliorating **hypertension** or high **blood pressure** involves orally administering (-)-**hydroxycitric acid**

Abstract (Basic):

... Treating or ameliorating **hypertension** or high **blood pressure** involves administering orally (-)-**hydroxycitric acid**.

... fat diet (30% of calories) for 60 days. These rats were fed water or potassium **hydroxycitrate** (KHCA) (0.33 mmols/kg) twice daily by gastric intubation. Five animals were used as...

...0.0026. Both of these factors played a role in the clinical findings of lowered **blood pressure** in **hypertensive** individuals...

...The (-)-**hydroxycitric acid** lowers elevated insulin and elevated stress hormone levels (preferably glucocorticoid levels) and thus reduces the elevated **blood pressure** level without any side effects. The treatment provides an improvement in the **blood pressure** metabolism that shows evidence of dysregulation...

? □

? SHOW FILES

File 5: Biosis Previews(R) 1969-2004/Nov W2
(c) 2004 BIOSIS
File 155: MEDLINE(R) 1951-2004/Nov W3
(c) format only 2004 The Dialog Corp.
File 16: Gale Group PROMT(R) 1990-2004/Nov 29
(c) 2004 The Gale Group
File 34: SciSearch(R) Cited Ref Sci 1990-2004/Nov W3
(c) 2004 Inst for Sci Info
File 71: ELSEVIER BIOBASE 1994-2004/Nov W2
(c) 2004 Elsevier Science B.V.
File 73: EMBASE 1974-2004/Nov W3
(c) 2004 Elsevier Science B.V.
File 51: Food Sci.&Tech.Abs 1969-2004/Nov W4
(c) 2004 FSTA IFIS Publishing
File 74: Int.Pharm.Abs 1970-2004/Nov B1
(c) 2004 Amer.Soc.of Health-Sys.Pharm.
File 351: Derwent WPI 1963-2004/UD,UM &UP=200475
(c) 2004 Thomson Derwent

?

?

? DS

Set	Items	Description
S1	168	(CITRIN OR GARCIN?) (S) (HYPERTEN? OR ANTIHYPERTEN? OR (BLD - OR BLOOD) (W) PRESSURE OR (WEIGHT OR WT) (5N) (CONTROL OR REDUC? - OR LOSS))

S2	111	RD (unique items)
----	-----	-------------------

S3	63	S2 NOT (PY=2004 OR PY=2003 OR PY=2002 OR PY=2001)
----	----	---

?

?

? T S3/3 AB KWIC/1-63

3/ABKWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012885468 BIOSIS NO.: 200100057307
Effects of (-)-hydroxycitric acid on appetitive variables
AUTHOR: Mattes Richard D (Reprint); Bormann Leslie
AUTHOR ADDRESS: Department of foods and Nutrition, Purdue University, 212
Stone Hall, West Lafayette, IN, 47907-1264, USA**USA
JOURNAL: Physiology and Behavior 71 (1-2): p87-94 October 1-15, 2000 2000
MEDIUM: print
ISSN: 0031-9384
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: (-)-Hydroxycitric acid (HCA) reportedly promotes weight loss, in part, through suppression of hunger. However, this mechanism has never been evaluated in humans in a controlled study. Eighty-nine mildly overweight females were prescribed 5020-kJ diets for 12 weeks as part of a double-blind, placebo-controlled parallel group study. Forty-two participants ingested 400-mg caplets of **Garcinia** cambogia 30-60 min prior to meals for a total dose of 2.4 g/day (1.2 g/day HCA). Forty-seven participants ingested matched placebos. Weight and body composition were assessed at baseline and every other week for 12 weeks. Food intake and appetitive variables were assessed at baseline and monthly for 12 weeks. Both groups lost body weight with the active group achieving a significantly greater reduction (3.7 +/- 3.1 kg versus 2.4 +/- 2.9 kg). No effects of the HCA were observed on appetitive variables. The active treatment group did not exhibit better dietary compliance or significant correlations between appetitive variables and energy intake or weight change. This study does not support a satiety effect of HCA.

...ABSTRACT: double-blind, placebo-controlled parallel group study.
Forty-two participants ingested 400-mg caplets of **Garcinia** cambogia 30-60 min prior to meals for a total dose of 2.4 g...

3/ABKWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012873379 BIOSIS NO.: 200100045218
A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin
AUTHOR: Thom E (Reprint)
AUTHOR ADDRESS: N-2001, Lillestrom, Norway**Norway
JOURNAL: Journal of International Medical Research 28 (5): p229-233 September-October, 2000 2000
MEDIUM: print
ISSN: 0300-0605
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The efficacy and tolerability of a new weight-reduction agent, based on natural ingredients, was investigated in this randomized, placebo-controlled, double-blind study. The product reduces the absorption of different types of sugar from the gastrointestinal tract.

Forty obese volunteers were included in the 12-week study. Body weight, body composition and blood pressure were recorded at baseline and every month during the study. The results show a significant difference in weight reduction in favour of the active group (3.5 kg versus 1.2 kg). Body composition measurements showed that > 85% of the reduction in the active group is fat loss. The tolerability was similar and good in both groups. This product shows promising results and should be studied more extensively at different dose levels.

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...**Garcinia** cambogia extract,
Phaseolus vulgaris extract, inulin, randomized double-blind
placebo-controlled trial, sugar absorption reduction

3/ABKWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0011746372 BIOSIS NO.: 199900006032
Garcinia cambogia (Hydroxycitric acid) as a potential antiobesity agent: A
randomized controlled trial
AUTHOR: Heymsfield Steven B (Reprint); Allison David B; Vasselli Joseph R;
Pietrobelli Angelo; Greenfield Debra; Nunez Christopher
AUTHOR ADDRESS: Obesity Res. Cent., 1090 Amsterdam Ave., 14th Floor, New
York, NY 10025, USA**USA
JOURNAL: JAMA (Journal of the American Medical Association) 280 (18): p
1596-1600 Nov. 11, 1998 1998
MEDIUM: print
ISSN: 0098-7484
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Context.-Hydroxycitric acid, the active ingredient in the herbal compound *Garcinia cambogia*, competitively inhibits the extramitochondrial enzyme adenosine triphosphate-citrate (pro-3S)-lyase. As a citrate cleavage enzyme that may play an essential role in de novo lipogenesis inhibition, *G. cambogia* is claimed to lower body **weight** and **reduce** fat mass in humans. Objective.-To evaluate the efficacy of *G. cambogia* for body **weight** and fat mass **loss** in overweight human subjects. Design.-Twelve-week randomized, double-blind, placebo-controlled trial. Setting.-Outpatient **weight control** research unit. Participants.-Overweight men and women subjects (mean body mass index (weight in kilograms divided by the square of height in meters), approximately 32 kg/m²). Intervention.-Subjects were randomized to receive either active herbal compound (1500 mg of hydroxycitric acid per day) or placebo, and both groups were prescribed a high-fiber, low-energy diet. The treatment period was 12 weeks. Body weight was evaluated every other week and fat mass was measured at weeks 0 and 12. Main Outcome Measures.-Body weight change and fat mass change. Results.-A total of 135 subjects were randomized to either active hydroxycitric acid (n = 66) or placebo (n = 69); 42 (64%) in the active hydroxycitric acid group and 42 (61%) in the placebo group completed 12 weeks of treatment (P=.74). Patients in both groups lost a significant amount of weight during the 12-week treatment period (P<.001); however, between-group **weight loss** differences were not statistically significant (mean (SD), 3.2 (3.3) kg vs 4.1 (3.9) kg; P=.14). There were no significant differences in estimated percentage of body fat mass loss between treatment groups, and the fraction of subject **weight loss** as fat was not influenced by treatment group. Conclusions.-

Garcinia rambogia failed to produce significant **weight loss** and fat mass **loss** beyond-that observed with placebo.

...ABSTRACT: an essential role in de novo lipogenesis inhibition, **G. cambogia** is claimed to lower body **weight** and **reduce** fat mass in humans. Objective.-To evaluate the efficacy of **G. cambogia** for body **weight** and fat mass **loss** in overweight human subjects. Design.-Twelve-week randomized, double-blind, placebo-controlled trial. Setting.-Outpatient **weight control** research unit. Participants.-Overweight men and women subjects (mean body mass index (weight in kilograms...

...significant amount of weight during the 12-week treatment period ($P<.001$); however, between-group **weight loss** differences were not statistically significant (mean (SD), 3.2 (3.3) kg vs 4.1...

...estimated percentage of body fat mass loss between treatment groups, and the fraction of subject **weight loss** as fat was not influenced by treatment group. Conclusions.-**Garcinia rambogia** failed to produce significant **weight loss** and fat mass **loss** beyond-that observed with placebo.

3/ABKWIC/4 (Item 4 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0011740217 BIOSIS NO.: 199800534464
A randomized clinical trial of the efficacy of **garcinia cambogia** for **weight** and fat **loss** in association with low calorie diet
AUTHOR: Heymsfield S B; Allison D B; Nunez C; Greenfield D; Wolper C; Pietrobelli A; Vasselli J R
AUTHOR ADDRESS: Obesity Res. Cent., Dep. Med., St. Luke's/Roosevelt Hosp., Columbia Univ., New York, NY, USA**USA
JOURNAL: International Journal of Obesity 22 (SUPPL. 3): pS268 Aug., 1998 1998
MEDIUM: print
CONFERENCE/MEETING: Eighth International Congress on Obesity Paris, France August 29-September 3, 1998; 19980829
SPONSOR: International Association for the Study of Obesity
ISSN: 0307-0565
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English

A randomized clinical trial of the efficacy of **garcinia cambogia** for **weight** and fat **loss** in association with low calorie diet

3/ABKWIC/5 (Item 5 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0010101065 BIOSIS NO.: 199698568898
Inhibition of citrate lyase may aid aerobic endurance
AUTHOR: McCarty M F
AUTHOR ADDRESS: Nutr. 21, 1010 Turquoise Street, Suite 335, San Diego, CA 92109, USA**USA
JOURNAL: Medical Hypotheses 45 (3): p247-254 1995 1995
ISSN: 0306-9877
DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Owing to a substantial increase in glucose uptake by working muscle, glucose homeostasis during sustained aerobic exercise requires a severalfold increase in hepatic glucose output. As exercise continues and liver glycogen declines, an increasing proportion of this elevated glucose output must be provided by gluconeogenesis. Increased gluconeogenic efficiency in trained individuals is a key adaptation promoting increased endurance, since failure of hepatic glucose output to keep pace with muscle uptake rapidly leads to hypoglycemia and exhaustion. Pre-administration of (-)-hydroxycitrate, a potent inhibitor of citrate lyase found in fruits of the genus *Garcinia*, may aid endurance during postabsorptive aerobic exercise by promoting gluconeogenesis. Carnitine and bioactive chromium may potentiate this benefit. The utility of this technique may be greatest in exercise regimens designed to promote **weight loss**.

...ABSTRACT: benefit. The utility of this technique may be greatest in exercise regimens designed to promote **weight loss**.

3/ABKWIC/6 (Item 6 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0008704685 BIOSIS NO.: 199395006951

Rademaker-Garcin syndrome associated with pallidal calcifications

AUTHOR: Masson G; Blin O (Reprint); Pouget J; Serratrice G

AUTHOR ADDRESS: Clin. Maladies Systeme Nerveux et Appareil Locomoteur, CHU Timone, 13385 Marseille, Cedex 05, France**France

JOURNAL: Revue Neurologique (Paris) 148 (8-9): p546-549 1992

ISSN: 0035-3787

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: French

ABSTRACT: We report gait abnormalities with exaggerated support against gravity in a 76 year-old woman. This exaggeration, and its demonstration by ankle dorsiflexion in supine position, was first described by Rademaker and **Garcin** (1933) as probably resulting from cerebellar brainstem lesions. In the present case, quantitative analysis of locomotion showed a strong reduction in both stride duration and stride length. There was an increased variability between two consecutive locomotor cycles and a large increase in both stance duration and relative double-support duration. Electromyography clearly showed leg **hypertension** following ankle dorsiflexion, contrasting with normal leg mobility in the supine patient. This suggested that reflexive antigravity support abnormalities could explain this pattern of locomotor disabilities, differentiating them from other kinds mchlt marche a petits pas mchgt . The present case was associated with bilateral pallidal calcifications, suggesting an involvement of the basal ganglia in support reaction against gravity and in control of adequate postural muscle tone necessary for locomotion.

...ABSTRACT: and its demonstration by ankle dorsiflexion in supine position, was first described by Rademaker and **Garcin** (1933) as probably resulting from cerebellar brainstem lesions. In the present case, quantitative analysis of...

...large increase in both stance duration and relative double-support duration. Electromyography clearly showed leg **hypertension** following ankle dorsiflexion, contrasting with normal leg mobility in the supine patient. This suggested that...

3/ABKWIC/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0003007812 BIOSIS NO.: 198070039299
SYNTHESIS AND PHARMACOLOGY OF MANGOSTIN 3 6 DI-O GLUCOSIDE
AUTHOR: PAI B R (Reprint); NATARAJAN S; SUGUNA H; KAMESWARAN L;
SHANKARANARAYAN D; GOPALAKRISHNAN C
AUTHOR ADDRESS: RES DEV LAB, AMRUTANJAN LTD, MADRAS-4, TAMIL NADU, INDIA**
INDIA
JOURNAL: Journal of Natural Products (Lloydia) 42 (4): p361-365 1979
ISSN: 0163-3864
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: A glucoside of mangostin [*Garcinia mangostana*] was synthesized and its structure was determined as mangostin-3,6-di-O-glucoside on the basis of spectral and analytical data. A study of its pharmacology indicated its CNS depressant activity. The diglucoside also produced a significant rise in **blood pressure** in rats.

...ABSTRACT: its pharmacology indicated its CNS depressant activity. The diglucoside also produced a significant rise in **blood pressure** in rats.

DESCRIPTORS: RAT GARCINIA-MANGOSTANA **BLOOD PRESSURE** CENTRAL
NERVOUS SYSTEM DEPRESSANT

3/ABKWIC/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0002918576 BIOSIS NO.: 198069032563
PHARMACOLOGICAL PROFILE OF MANGOSTIN AND ITS DERIVATIVES
AUTHOR: SHANKARANARAYAN D (Reprint); GOPALAKRISHNAN C; KAMESWARAN L
AUTHOR ADDRESS: DEP PHARMACOL, MADRAS MED COLL, MADRAS 600 003, TAMIL NADU,
INDIA**INDIA
JOURNAL: Archives Internationales de Pharmacodynamie et de Therapie 239 (2)
) : p257-269 1979
ISSN: 0003-9780
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Mangostin (M), a naturally occurring xanthone in the rinds of the fruits of *Garcinia mangostana* (Guttiferae) and its derivatives, i.e., 3-O-methyl mangostin (MM), 3,6-di-O-methyl mangostin (DM), 1-isomangostin (IM), mangostin triacetate (MT), mangostin 3,6-di-O-(tetra acetyl) glucoside (MTG) and mangostin-3,6-di-O-glucoside (MOG) were screened for various pharmacological effects in experimental animals. With the exception of DM all the test compounds produced CNS depression characterized by ptosis, sedation, decreased motor activity, potentiation of pentobarbital sleeping time and ether anesthesia in mice and rats. No compound exhibited analgesic, antipyretic and anticonvulsant effects.

With the exception of MOG, no test compound produced significant effects on the cardiovascular system of frogs and dogs. MOG produced myocardial stimulation and a rise in **blood pressure** which was partially blocked by propranolol. M, IM and MT produced pronounced anti-inflammatory activity both by i.p. and oral routes in rats as tested by carrageenin-induced hind paw edema, cotton pellet implantation and granuloma pouch techniques. Anti-inflammatory activity for M, IM and MT was seen even in bilaterally adrenalectomized rats. M, IM and MT did not produce any mast cell membrane stabilizing effect and the degranulation effect of polymyxin B, diazoxide and Triton X-100 on rat peritoneal mast cells in vitro was not prevented. M, IM and MT did not alter the prothrombin time of albino rats. M alone produced significant anti-ulcer activity in rats.

...ABSTRACT: the cardiovascular system of frogs and dogs. MOG produced myocardial stimulation and a rise in **blood pressure** which was partially blocked by propranolol. M, IM and MT produced pronounced anti-inflammatory activity...

3/ABKWIC/9 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

14518262 PMID: 10516985

Nutrition and dietary supplements.

Fillmore C M; Bartoli L; Bach R; Park Y

Pendleton Community Care, Franklin, West Virginia, USA.

Physical medicine and rehabilitation clinics of North America (UNITED STATES) Aug 1999, 10 (3) p673-703, ISSN 1047-9651 Journal Code: 9102787

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Quality and number of subjects in blinded controlled clinical trials about the nutrition and dietary supplements discussed here is variable. Glucosamine sulfate and chondroitin sulfate have sufficient controlled trials to warrant their use in osteoarthritis, having less side effects than currently used nonsteroidal anti-inflammatory drugs, and are the only treatment shown to prevent progression of the disease. Dietary supplements of ephedrine plus caffeine for weight loss (weight loss being the current first line recommendation of physicians for osteoporosis) show some promise, but are not sufficient in number of study subjects. Phenylpropanolamine is proven successful in weight loss. Both ephedrine and phenylpropanolamine have resulted in deaths and hence are worrisome [table: see text] as an over-the-counter dietary supplement. Other commonly used weight loss supplements like Cola acuminata, dwarf elder, Yohimbine, and **Garcinia** camborgia are either lacking controlled clinical trials, or in the case of the last two supplements, have clinical trials showing lack of effectiveness (although **Garcinia** has been successful in trials as part of a mixture with other substances, it is unclear if it was a necessary part of the mixture). Safety of these **weight loss** supplements is unknown. Chromium as a body building supplement for athletes appears to have no efficacy. Creatine may help more in weight lifting than sprinting, but insufficient study subjects and safety information make more studies necessary. Carbohydrate loading is used commonly before endurance competitions, but may be underused as it may be beneficial for other sport performances. Supplements for muscle injury or cramps have had too few studies to determine efficacy. Although proper rehydration with fluids and electrolytes is necessary, a paucity of actual studies to maximize

prophylactic treatment for exercise induced cramping still exists. Nutritional supplements for cardiovascular disorders are generally geared to prevention. The United States Department of Agriculture has good recommendations to prevent atherosclerosis; a stricter version by Ornish was shown to reverse coronary heart disease, and the low meat, high fruit, and vegetable DASH diet has been found to decrease **hypertension**. The epidemiologic studies of hyperhomocysteinemia are impressive enough to give folic acid (or vitamin B6 or B12) supplements to those with elevated homocysteine levels and test patients who have a history of atherosclerotic disease, but no controlled clinical trials have been completed. Soluble fiber has several positive studies in reduction of cholesterol levels and generally is accepted. The data on vitamin E are the most confusing. This vitamin was not helpful in cerebrovascular prevention in China and not helpful at relatively small doses (50 mg) in the United States or Finland against major coronary events. Levels of 400 mg appeared to decrease cardiovascular disease in the United States in studies based on reports by patients and in one large clinical trial. Vitamin E also was successful in prevention of restenosis after PTCA in one clinical trial. Both of these clinical trials need to be repeated in other developed country populations. Some nutritional and dietary supplements are justifiably useful at this point in time. Several meet the criteria of a late Phase 3 FDA clinical trial (where it would be released for public use), but many dietary supplements have insufficient numbers of studies. Some deaths also have occurred with some supplements. If these supplements were required to undergo clinical trials necessary for a new drug by the FDA, they would not be released yet to the public. Several nontoxic supplements appear promising, though need further study. Because they have essentially no toxicity (such as folic acid with B12, soluble fiber, and vitamin E) and may have efficacy, some of these supplementations may be useful now, without randomized clinical trials.

... dietary supplement. Other commonly used weight loss supplements like *Cola acuminata*, dwarf elder, Yohimbine, and *Garcinia cambogia* are either lacking controlled clinical trials, or in the case of the last two supplements, have clinical trials showing lack of effectiveness (although *Garcinia* has been successful in trials as part of a mixture with other substances, it is unclear if it was a necessary part of the mixture). Safety of these **weight loss** supplements is unknown. Chromium as a body building supplement for athletes appears to have number..

... and the low meat, high fruit, and vegetable DASH diet has been found to decrease **hypertension**. The epidemiologic studies of hyperhomocysteinemia are impressive enough to give folic acid (or vitamin B6...

3/ABKWIC/10 (Item 2 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2004 The Dialog Corp. All rts. reserv.

14424557 PMID: 10422988
Garcinia cambogia for **weight loss**.
 Firenzuoli F; Gori L
 JAMA - the journal of the American Medical Association (UNITED STATES)
 Jul 21 1999, 282 (3) p234; author reply 235, ISSN 0098-7484
 Journal Code: 7501160
 Document type: Letter
 Languages: ENGLISH
 Main Citation Owner: NLM
 Record type: Completed

Garcinia cambogia for **weight loss**.

3/ABKWIC/11 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

14424556 PMID: 10422987
Garcinia cambogia for **weight loss**.
Schaller J L
JAMA - the journal of the American Medical Association (UNITED STATES)
Jul 21 1999, 282 (3) p234; author reply 235, ISSN 0098-7484
Journal Code: 7501160
Comment on JAMA. 1998 Nov 11;280(18) 1596-600; Comment on PMID 9820262
Document type: Comment; Letter
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Garcinia cambogia for **weight loss**.

3/ABKWIC/12 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

14424555 PMID: 10422986
Garcinia cambogia for **weight loss**.
Badmaev V; Majeed M; Conte A A
JAMA - the journal of the American Medical Association (UNITED STATES)
Jul 21 1999, 282 (3) p233-4; author reply 235, ISSN 0098-7484
Journal Code: 7501160
Comment on JAMA. 1998 Nov 11;280(18) 1596-600; Comment on PMID 9820262
Document type: Comment; Letter
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Garcinia cambogia for **weight loss**.

3/ABKWIC/13 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

06389644 PMID: 6100985
[Jugular chemodectoma with Garcin syndrome]
Quemodectoma yugular con sindrome de Garcin.
Chouza C; Navarro A; Purriel J A; Pou G; de Tenyi A; Wozniak A; Touya J
Instituto de Neurologia, Montevideo, Uruguay.
Acta neurologica latinoamericana (URUGUAY) 1981, 27 (3-4) p155-66,
ISSN 0001-6306 Journal Code: 9421556
Document type: Case Reports; Journal Article ; English Abstract
Languages: SPANISH
Main Citation Owner: NLM
Record type: Completed
The authors present an exceptional case of chemodectoma jugulare with important invasion of the skull base involving all the cranial nerves on one side and conforming Garcin's syndrome. Practically all the possible ways of spreading were followed by the tumor, with involvement of the posterior, middle and anterior fossas of the skull base and also orbit, middle ear and neck. The clinical and histopathological difficulties in the diagnosis, especially when the chemodectoma has only neurological signs,

are stressed. The association of otologic symptoms makes the diagnosis easier. The patient had an early onset of the symptoms and a rapid evolution considering this type of tumors. The appearance of goitre in this patient is a sign of endocrine disturbance, which is occasionally associated with these tumors. Apparently this chemodectoma was not a secreting tumor, since the **blood pressure** values were normal. No signs of multicentricity or metastatic growths were detected. The radiological studies, and especially computerized tomography scanning, gave precise information about the spreading of the tumor. The authors consider that the knowledge of this entity is important in order to arrive at a correct diagnosis.

... occasionally associated with these tumors. Apparently this chemodectoma was not a secreting tumor, since the **blood pressure** values were normal. No signs of multicentricity or metastatic growths were detected. The radiological studies...

3/ABKWIC/14 (Item 6 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

01484551 PMID: 13036012 Record Identifier: 5324-6154-317-705
[Citrin in hypertension]
Tsitrin pri gipertonicheskoi bolezni.
DZHEMS-LEVI D E
Klinicheskaja meditsina (Not Available) Jan 1953, 31 (1) p82-3,
ISSN 0023-2149 Journal Code: 2985204R
Document type: Journal Article
Languages: UNSPECIFIED
Main Citation Owner: NLM
Other Citation Owner: CLML
Record type: Completed

[Citrin in hypertension]

3/ABKWIC/15 (Item 1 from file: 16)
DIALOG(R) File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

07668051 Supplier Number: 63843992
SLIMMING CITRIN.
Health Products Business, v46, n7, p63
July, 2000
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Trade
Word Count: 63

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

Muhammed Majeed, Ph.D., et. al., developed **Citrin**: A Revolutionary, Herbal Approach to Weight Management based on scientific data from clinical research on **Garcinia cambogia**. They consider this native Indian fruit, used to make the commercial product **Citrin**, a natural source for treating obesity. The final chapter in this booklet answers common questions about **weight control**. New Editions Publishing; 70 p., \$3.95.

3/ABKWIC/16 (Item 2 from file: 16)
DIALOG(R) File 16:Gale Group PROMT(R)

(c) 2004 The Gale Group. All rts. reserv.

07519094 Supplier Number: 63019694
Peace Mountain Skinny Water MANUFACTURER: Peace Mountain Natural Beverages
Corp. CATEGORY: 215 - Bottled Waters. (Brief Article)
Product Alert, v30, n10, pNA
May 22, 2000
Language: English Record Type: Fulltext
Article Type: Brief Article
Document Type: Newsletter; Trade
Word Count: 187

Promotional literature states, "A beverage that is low in calories, helps with **weight loss**... Skinny Water is a high magnesium spring water infused with the natural appetite suppressant: Super...

...selling safe all-natural diet ingredient extract. Super CitriMax is made from the fruit of **Garcinia** cambogia which makes you feel full...
Skinny Water is a unique, patent-pending kosher formula...

3/ABKWIC/17 (Item 3 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

07108693 Supplier Number: 60036893
Atkins Supplement - Basic #3; Dieters' Advantage; Basic #1 MANUFACTURER:
Atkins Nutritionals, Inc. CATEGORY: 362 - Dieting Aids.
Product Alert, v30, n4, pNA
Feb 28, 2000
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 212

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...ingredient formula, has been specifically reformulated to further ensure effective nutritional support during low carb **weight loss**.
Basic #3 is said to contain higher levels of chromium and vanadium than traditional multivitamin...

...as well as aid in fat metabolism. The new formula now combines over 1800mg of **citrin**, 300mcg of chromium and 100mg of l-carnitine, along with other support vita-nutrients in...

...lower levels of many vita-nutrients, reflecting the lower needs of vita-nutrient support during **weight** maintenance vs. **weight loss**." For sample retrieval information, please call: Marketing Intelligence Service, Ltd., (716) 374-6326.

3/ABKWIC/18 (Item 4 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

06944863 Supplier Number: 58618405
Atkins Nutritionals Responds to Changing Needs With Improved Vita-Nutrient Formulations.
PR Newswire, p3867
Jan 18, 2000
Language: English Record Type: Fulltext
Document Type: Newswire; Trade

Word Count: 522

... uniquely complements the Basic #3 multivitamin formula by offering additional nutritional support during low-carb **weight loss**. Dieters' Advantage is free of all stimulants, including ephedra and caffeine, and now has added...

...central nervous system stimulants or jitters. The new formula now combines over 1800 mg of **Citrin**, 300 mcg of Chromium, and 100 mg of l-carnitine, along with other support vita...

3/ABKWIC/19 (Item 5 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

06841426 Supplier Number: 57762961
Enforma Natural Products.
Drug Store News, v21, n18, p71
Nov 15, 1999
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Trade
Word Count: 147

Exercise In A Bottle combines natural thermogenics, including calcium pyruvate **garcinia** cambogia, chromium and ginkgo, and serves to support increased activity levels and digestion, especially during **weight loss**.

The system also includes a consumer pamphlet, which underscores the importance of exercise to any...

3/ABKWIC/20 (Item 6 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

06114415 Supplier Number: 53713598
Natural cures: herbs are huge, but do they work?
Kanter, Larry
Los Angeles Business Journal, v21, n3, p1(2)
Jan 18, 1999
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Tabloid; Trade
Word Count: 1618

... had no significant impact on the number, duration or severity of colds. And extracts of **Garcinia** cambogia, an ingredient in more than 30 dietary supplements marketed for **weight loss**, were found to have no effectiveness whatsoever in a study by Columbia University researchers.

The...

3/ABKWIC/21 (Item 7 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

06011235 Supplier Number: 53413782
Quigley Corporation, Makers of COLD-EEZE(R), Announce January Launch of **BODYMATE(TM)** and **KIDS-EEZE(TM)** at Walgreen's.
PR Newswire, p0929
Dec 16, 1998

Language: English Record Type: Fulltext
Document Type: Newswire; Trade
Word Count: 449

... diet. The key ingredient of the lozenge is (-) hydroxycitric acid (HCA), an extract from the **Garcinia** Cambogia plant, the powdered root of which has been used for centuries in Thailand and...

...trials. BODYMATE(TM) lozenges are packaged in four gourmet flavors and supplied with an uncomplicated **weight control** program.

The homeopathic KIDS-EEZE(TM) version of COLD-EEZE(R) follows the exact formulation...

3/ABKWIC/22 (Item 8 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05986435 Supplier Number: 53346396
Nova Naturals Dietary Supplement - NxBloc Capsules; NxTrim Protein Meal
Replacement Powder MANUFACTURER: Nova Pharmaceutical, Inc. CATEGORY: 362
- Dieting Aids.
International Product Alert, v28, n22, pNA
Nov 23, 1998
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 158

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...blood triglycerides and body fat accumulation. Claimed to help control appetite and craving, the ingredients **garcinia** cambogia and gymnemic acid are also included in the Capsules. Another product, NxTrim Protein Meal...

...low calorie, low sugar and low carbohydrate drink designed to be used in conjunction with **weight-loss** programs. Available in Powder form, it is said to be high in protein and has...

3/ABKWIC/23 (Item 9 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05976337 Supplier Number: 53277204
Herbals, vitamins featured in JAMA issue devoted to alternative medicine.
Food Chemical News, v40, n40, pNA
Nov 23, 1998
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 573

... when treated with Chinese herbs compared to those treated with a placebo.

Another study found **loss** in body **weight** and fat mass were no different in overweight patients treated with a high-fiber, low-energy diet and **Garcinia** cambogia, (Hydroxycitric Acid) a potential anti-obesity agent, than in those treated with diet and...

3/ABKWIC/24 (Item 10 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)

(c) 2004 The Gale Group. All rts. reserv.

05965641 Supplier Number: 53247531
PUBLIC USING MORE ALTERNATIVE CARE.
Moore, J. Duncan
Modern Healthcare, p16(1)
Nov 16, 1998
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Professional
Word Count: 318

... headaches.
* Chinese herbs can help some people with irritable bowel syndrome.
* The anti-obesity agent **garcinia** cambogia in herbal compounds
does not lead to **weight loss**.
* Neither acupuncture nor the drug amitriptyline hydrochloride
relieves pain caused by HIV-related peripheral neuropathies...

3/ABKWIC/25 (Item 11 from file: 16)
DIALOG(R) File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05824562 Supplier Number: 50333028
SWEET DIET
Levy, Sandra
Drug Topics, v142, n18, p52
Sept 21, 1998
Language: English Record Type: Fulltext
Article Type: Article
Document Type: Magazine/Journal; Trade
Word Count: 450

... conducted two years ago on 42 subjects who used Garcinia cambogia
and chromium to lose **weight**. An average **weight loss** of
10.8 lb. each was reported.
A package of Bodymate contains 84 gourmet lozenges...

3/ABKWIC/26 (Item 12 from file: 16)
DIALOG(R) File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05663906 Supplier Number: 50126465
Diet & Health Foods: Kasane Hanbai Launches Soy peptide Health Drinks
Comline-Consumer Goods, pN/A
June 23, 1998
Language: English Record Type: Fulltext
Article Type: Article
Document Type: Newswire; Trade
Word Count: 67

(USE FORMAT 7 FOR FULLTEXT)
TEXT:
...protein. Fitriess Peptide is good for a protein supplement drink after
sporting activities. And Fitness **Garcinia**, which contains
garcinia besides soy peptide, has been designed to achieve
weight loss healthily. Price: Y220 per 100- 120ml glass bottle.

3/ABKWIC/27 (Item 13 from file: 16)
DIALOG(R) File 16:Gale Group PROMT(R)

(c) 2004 The Gale Group. All rts. reserv.

05644782 Supplier Number: 50094281
Beauty & Health Foods: "Garcinia Beauty" by Nisshin Science
Comline-Consumer Goods, pN/A
June 12, 1998
Language: English Record Type: Fulltext
Article Type: Article
Document Type: Newswire; Trade
Word Count: 91

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

The product is a new **garcinia**-based diet food which allows the consumer to achieve **weight loss** simply by eating it before meals. **Garcinia** is a fruit native to Southeast Asian regions, and in India, for example, it is...

...fat within the body and suppress the appetite. One tablet contains 125mg (HCA: 50mg) of **garcinia** extract. A 125g package of 250 tablets of 500mg costs Y2800.

3/ABKWIC/28 (Item 14 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05604874 Supplier Number: 48481321
Diet & Health Foods: Garcinia Beauty by Nisshin Science
Comline-Consumer Goods, pN/A
May 13, 1998
Language: English Record Type: Fulltext
Document Type: Newswire; Trade
Word Count: 94

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

Garcinia Beauty by Nisshin Science is a new **garcinia**-based diet food which allows the consumer to achieve **weight loss** simply by eating it before meals. **Garcinia** is a fruit native to Southeast Asian regions, and in India, for example, it is...

...fat within the body and suppress the appetite. One tablet contains 125mg (HCA: 50mg) of **garcinia** extract. A 125g package of 250 tablets of 500mg costs Y2800.

3/ABKWIC/29 (Item 15 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05582209 Supplier Number: 48451127
Tribal Tonics Herbal Supplement.
Lookout (Foods Edition), v21, n8, pn/a
April 28, 1998
Language: English Record Type: Abstract
Document Type: Magazine/Journal; Trade

ABSTRACT:

Apple & Eve, LP of Roslyn, NY, launches a line of functional beverage under the brand name, Tribal Tonics, with each Herbal Supplement variety positioned for specific use. The Herbal Slimmer variety is a non-carbonated

green tea beverage that is flavored with grapefruit and contains ginseng and **garcinia** fruit. The **garcinia** fruit is claimed to contain HCA, which is reportedly prevent fat production and **reduce weight** gain. Tribal Tonics' other varieties are Relaxation Cocktail in an Island Peach flavor, Mental Refresher in Raspberry Tangerine, Immune Boost in a Lemon Ginger flavor and Energy Elixer in Mango Peach.

ABSTRACT:

...a non-carbonated green tea beverage that is flavored with grapefruit and contains ginseng and **garcinia** fruit. The **garcinia** fruit is claimed to contain HCA, which is reportedly prevent fat production and **reduce weight** gain. Tribal Tonics' other varieties are Relaxation Cocktail in an Island Peach flavor, Mental Refresher...

3/ABKWIC/30 (Item 16 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05559127 Supplier Number: 48422021
Trace Minerals Dietary Supplement - In Control Tablets; Ephedra Free In
Control Tablets MANUFACTURER: Trace Minerals Research CATEGORY: Dieting
Aids
Product Alert, v28, n7, pN/A
April 13, 1998
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 119

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...In Control, a new "diet and wellness formula" Dietary Supplement made with chromium, L-carnitine, **garcinia** cambogia, ConcenTrace(r) and panax ginseng in a base of dandelion root and kelp. According to the company, In Control is designed to nourish the body while supporting **weight loss**. Some of the vitamins and nutrients contained in the Capsules are folic acid, vitamin B1...

3/ABKWIC/31 (Item 17 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05519225 Supplier Number: 48365356
Body Care: "Solid Shape" by Oppen Cosmetics
Comline-Consumer Goods, pN/A
March 19, 1998
Language: English Record Type: Fulltext
Document Type: Newswire; Trade
Word Count: 145

... and prevents the formation of cellulite and gets rid of sagging. The "Diet Tablet" includes **Garcinia** Cambodia extract, which helps **reduce weight**, and Gymnema Sylvestre extract, which suppresses the absorption of sugar into the body. The "Super...

3/ABKWIC/32 (Item 18 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05421455 Supplier Number: 48223247

Nature's Dream Cookies - Diet
Product Alert, v28, n1, pN/A
Jan 12, 1998
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 174

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...Cookies are available from Walnut, CA-based Nature's Dream. Promoted ingredients include opuntia streptacantha, **garcinia** cambogia and acetyl L-carnitine. Designed to stop cravings for food by helping you feel ...

...oz. Diet Cookie(tm) contains 90 calories and may also be used to help maintain **weight loss**. Each 1 oz. Nature's Dream Smart Cookie contains 2,500mg of Smart People Mix...

3/ABKWIC/33 (Item 19 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05353029 Supplier Number: 48142014
Ayurvedic Concepts Dietary Supplement - Lean Care Capsules
Product Alert, v27, n22, pN/A
Nov 24, 1997
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 78

... Ayurvedic Concepts has extended its Dietary Supplement product line to offer Lean Care Capsules containing **garcinia**. Sixty capsules are presented in an overboxed plastic bottle under its Ayurvedic Concepts banner. Ad copy describes it as a complex herbal formula that is said to regulate lipid metabolism. **Weight control** and body fat **reduction** uses are indicated. For sample retrieval information, please call: Marketing Intelligence Service, Ltd., (716) 374...

3/ABKWIC/34 (Item 20 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05133598 Supplier Number: 47836255
NutriSource CitriMax "The Ultimate" Nutritional Diet Shake - Vanilla
Product Alert, v27, n13, pN/A
July 14, 1997
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 153

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

NutriSource Corp. of Pleasant Hill, CA, is marketing three licensed herbal **weight reduction** products bearing both NutriSource and CitriMax names. One of the products is dubbed "The Ultimate...

...servings. Described in company literature as an allnatural plant extract derived from the exotic fruit **garcinia** cambogia, CitriMax is a registered trademark of InterHealth Nutritionals, Inc. It is also stated in ...

3/ABKWIC/35 (Item 21 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

05133597 Supplier Number: 47836254
NutriSource CitriMax Herbal Supplement - Tropical Flavored Liquid; Plus
ChromeMate Capsules
Product Alert, v27, n13, pN/A
July 14, 1997
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 152

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

Pleasant Hill, CA-based NutriSource Corp. is distributing three licensed **weight reduction** products bearing both NutriSource and CitriMax names. Used as an addition to your favorite beverage...

...Each scoop provides "1000mg (-) hydroxycitric acid, (500mg HCA) (a component derived from the exotic fruit **garcinia** cambogia)." It is packaged in a tamper evident 11 oz. plastic bottle containing 66 teaspoon
...

...Herbal Supplement is touted as "picolinic acid free... made from the all natural plant extract **Garcinia** Cambogia, combined with a patented niacin-bound (for better absorption) chromium supplement." Offered in 90...

3/ABKWIC/36 (Item 22 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04874140 Supplier Number: 47168377
Looking for quick and easy losses
OTC Update, n83, pN/A
March 1, 1997
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 3529

... 80% of turnover (fig 4, p80). Stella Pharmaceutical's Slim Fast continues to dominate the **weight-loss** component of the meal replacement/nutritional supplements category, according to Brenda Embree, director of marketing...

...sales of diet aid pills. Stella launched two new Dexatrim products in 1996: Dexatrim with **Garcinia** Cambogia and Dexatrim with Niacin-Bound Chromium. Both products are being promoted through print media...

3/ABKWIC/37 (Item 23 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04837748 Supplier Number: 47117502
Natural Balance DHEA Super Hormone Diet Supplement - Weight Control Formula
MANUFACTURER: Natural Balance, Inc. CATEGORY: Dieting Aids
Product Alert, v26, n3, pN/A
Feb 10, 1997

Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 87

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...Inc. and distributed by Pep Products, Inc. Hailed as, "A significant breakthrough for dieters," this **Weight Control** Formula combines the properties of "proven fat-fighters **Citrin**, carnitine and DynaChrome, a readily absorbed form of chromium." The capsules come in 60 ct...

3/ABKWIC/38 (Item 24 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04806138 Supplier Number: 47071585
Slim-Lite 0 Calorie Fruit Flavored Soft Drink with CitriMax - Blackberry; Strawberry; Peach; Raspberry; Kiwi-Strawberry MANUFACTURER: Citri-Lite Co., Inc. CATEGORY: Miscellaneous Soft Drinks
Product Alert, v27, n2, pN/A
Jan 27, 1997
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 159

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...acid (HCA) which comes from a tropical fruit, a species of the citrus family called **Garcinia**." Literature further states, "Slim-Lite works by providing HCA, which temporarily inhibits the formation of...

...storage of fat in the body, increases the amount of calories for energy, improves appetite **control** and can help you lose **weight**." Slim-Lite is also said to be sodium free and to contain NutraSweet. The suggested...

3/ABKWIC/39 (Item 25 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04751474 Supplier Number: 46993562
Fat Inhibitor Dietary Supplement - Caplets MANUFACTURER: Thompson Medical Company, Inc. CATEGORY: Dieting Aids
Product Alert, v26, n24, pN/A
Dec 23, 1996
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 125

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...Caplets. Package copy further states, "High fiber/low fat diet and exercise plan - a new **weight loss** plan to help you fight fat 3 ways - burn fat - reduce pounds and inches - trim...

...your body fast." This plan is "accompanied by a unique blend of ingredients, including chromium, **garcinia**, cambogia, thermogenic herbs, lipotropics (lecithin and choline) and an all-natural Fiber Blend," as well as containing "standardized panax ginseng extract to supplement

your **weight loss** program." Manufactured by Thompson Medical Co., Inc., located in West Palm Beach, FL, the product...

3/ABKWIC/40 (Item 26 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04665247 Supplier Number: 46865480
Kanebo Diet Gum MANUFACTURER: Kanebo Foods CATEGORY: Dieting Aids
International Product Alert, v13, n21, pN/A
Nov 4, 1996
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 107

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...Foods is the manufacturer behind the launch of a Diet Gum that is based on **Garcinia**, a South-east Asian fruit that reportedly aids in **weight-loss**. According to trade literature in New Foods Products in Japan, the fruit contains a substance...

...acids and promotes production of glycogen, an agent that suppresses hunger pangs. In addition to **Garcinia**, the gum contains vitamins and vegetable fiber and is sweetened with Aspartame. Each piece contains...

3/ABKWIC/41 (Item 27 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04401763 Supplier Number: 46457238
Eagle Health Weight Loss Supplement - Cactu-Slim Capsules MANUFACTURER:
Eagle Health Technologies CATEGORY: Dieting Aids
Product Alert, v26, n11, pN/A
June 10, 1996
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 167

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

A **Weight Loss** Supplement called Cactu-Slim is on the market in 90-count and 180-count containers...

...750mg Capsules are said to contain 450mg of cactus (nopal) opuntia steptacantha, and 300mg of **Citrin** (tm), which is **garcinia** cambogia extract - equal to 150mg of hydroxy-citric acid. Label copy states, "Cactus leaves are..."

3/ABKWIC/42 (Item 28 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04353107 Supplier Number: 46384296
Outback Blends Weight Management Snack Bars - Chocolate Crunch; Yogurt Crunch MANUFACTURER: Emu Man Pty. Ltd. CATEGORY: Special Diet Foods
Product Alert, v26, n9, pN/A
May 13, 1996
Language: English Record Type: Fulltext

Document Type: Newsletter; Trade
Word Count: 142

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...based Emu Man Pty. Ltd. Promotional literature states, "The main ingredient in the Outback Blends **weight loss** products is CitriMax. CitriMax is a standardized extract of the fruit of the Asian **garcinia** cambogia plant. CitriMax is rich in HCA, a compound that clinical studies have shown decreases...

3/ABKWIC/43 (Item 29 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04353106 Supplier Number: 46384295
Outback Blend Weight Management Coffee; Body Control Capsules MANUFACTURER:
Emu Man Pty. Ltd. CATEGORY: Dieting Aids
Product Alert, v26, n9, pN/A
May 13, 1996
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 153

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

Outback Blends brand **Weight** Management Coffee and Body **Control** Capsules are marketed by Burnet, TX-based Emu Man Pty. Ltd. Promotional literature states, "The main ingredient in the Outback Blends **weight loss** products is CitriMax. CitriMax is a standardized extract of the fruit of the Asian **garcinia** cambogia plant. CitriMax is rich in HCA, a compound that clinical studies have shown decreases...

3/ABKWIC/44 (Item 30 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04201422 Supplier Number: 46144284
Action Labs Supplement - Appe-Slim Tablets MANUFACTURER: Action Labs
CATEGORY: Dieting Aids
Product Alert, v26, n3, pN/A
Feb 12, 1996
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 107

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

Appe-Slim is described as a natural and effective appetite suppressant and **weight loss** Supplement product. Sixty Tablets are presented in a plastic bottle with label copy which states...

...of the key ingredients is said to be CitriMax derived from the natural exotic fruit **Garcinia** Cambogia. CitriMax is claimed to be clinically proven to assist the body in controlling the...

3/ABKWIC/45 (Item 31 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

04166988 Supplier Number: 46085725
Ultra Diet Pep 2000 Weight Control Capsules MANUFACTURER: Pep Products,
Inc. CATEGORY: Dieting Aids
Product Alert, v26, n2, pN/A
Jan 22, 1996
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 84

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...all natural way to lose weight and energize your diet are Ultra Diet Pep 2000 **Weight Control** Capsules. The capsules are said to curb appetite and block fat with **citrin** and dynaChrome chromium. One box contains 60 capsules and has a retail price of \$14...

3/ABKWIC/46 (Item 32 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

03950052 Supplier Number: 45719212
Now Dietary Supplement - Citrin & Chromium Capsules MANUFACTURER: Now
Natural Foods CATEGORY: Dieting Aids
Product Alert, v25, n32, pN/A
August 7, 1995
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 92

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

Ninety **Citrin** & Chromium Capsules are packaged in a bottle under the Now brand name. The Dietary Supplement is a product of Now Natural Foods, located in Glendale Heights, IL. Company literature states, "**Citrin** (r) is a standardized extract derived from the rind of the **garcinia** cambogia fruit in India. This natural extract contains (-)HCA, which has been researched as an...

...diet ingredient. Add in 100mcg of chromium picolinate and you get one of the best **weight-loss** formulas available." For sample retrieval information, please call: Marketing Intelligence Service, Ltd., (716) 374 -6326.

3/ABKWIC/47 (Item 33 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

03930187 Supplier Number: 45681279
Diet Aids Market Rebounds, Driven By New Formulations
Research Alert, v13, n14, pN/A
July 21, 1995
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 211

... appetite suppressant products, while new herbal compounds continue to be introduced. The most promising new **weight -loss** herbal ingredient is the Indian fruit, **garcinia** cambogia, which contains a fruit acid which reduces appetite, increases energy and speeds up fat...

3/ABKWIC/48 (Item 34 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

03748122 Supplier Number: 45321164
Ultra Slender Premium Citrimax Herbal Weight Loss Formula Tablets; Ultra
Citrimax Weight Loss Formula Tablets; Soft Gel Weight Loss Formula
Tablets; Weight Main
Product Alert, v0, n0, pN/A
Feb 6, 1995
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 211

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...the Ultra Slender brand name in overboxed bottles containing 60 Tablets
are Premium CitriMax Herbal **Weight Loss** Formula (a broad
spectrum deluxe formula combined with a synergistic blend of herbs and
lipotropic factors to enhance the **weight loss** process), Soft
Gel **Weight Loss** Formula (a dietary tonic with ephedra (ma
huang), ChromeMate and guarana... to raise the body...

...body of excess fluids due to normal monthly changes or improper diet).
The Ultra CitriMax **Weight Loss** Formula (an advanced
weight loss formula) comes in a 90-count package. For sample
retrieval information, please call: Marketing Intelligence...

3/ABKWIC/49 (Item 35 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

03735663 Supplier Number: 45298823
Body Gold Supplement - CitriGold Capsules MANUFACTURER: Body Gold CATEGORY:
Dieting Aids
Product Alert, v0, n0, pN/A
Jan 30, 1995
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 63

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...Supplements from La Jolla, CA-based Body Gold. This product has "the
dynamic, clinically demonstrated **weight-loss** benefits of
natural extract hydroxycitric acid (HCA) from **Citrin** (r) and chromium
picolinate in one powerful formula." The Capsules are sold in a 180...

3/ABKWIC/50 (Item 36 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

03707355 Supplier Number: 45250412
Kiss Your Fat Goodbye Diet Supplement MANUFACTURER: National Health
Products CATEGORY: Dieting Aids
Product Alert, v26, n1, pN/A
Jan 8, 1995
Language: English Record Type: Fulltext

Document Type: Newsletter; Trade
Word Count: 60

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

...Health Products. Kiss Your Fat Goodbye was designed to be used in conjunction with a **weight loss** program and contains ingredients such as **citrin K**, chromium picolinate and L-carnitine. For sample retrieval information, please call: Marketing Intelligence Service...

3/ABKWIC/51 (Item 37 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

03696968 Supplier Number: 45232948
Fat CONTROLLERS
Beauty Counter, v0, n0, p20
Jan, 1995
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Trade
Word Count: 1860

... Fat Control Nutritional Complex, and it could herald the future face of slimming and appetite **control**.

Weight Logic comes in the form of tablets which claim to suppress hunger and prevent the...

3/ABKWIC/52 (Item 38 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

03634081 Supplier Number: 45124926
Esteem Plus Diet Formula MANUFACTURER: Esteem Products Ltd. CATEGORY:
Dieting Aids
Product Alert, v0, n0, pN/A
Nov 7, 1994
Language: English Record Type: Fulltext
Document Type: Newsletter; Trade
Word Count: 142

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

Esteem Plus Diet Formula is dubbed "The Permanent Solution" to lasting **weight loss** through **reduced** food intake, increased fat metabolism, and curbed cravings for sweets. It is designed to help...

...product known. It is derived from a native fruit-bearing plant of South Asia called **garcinia** cambogia. "Its efficacy and superior potency has been confirmed by research experts at Rutgers University...

3/ABKWIC/53 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2004 Inst for Sci Info. All rts. reserv.

09196510 Genuine Article#: 377WJ Number of References: 33
Title: Effects of acute (-)-hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans (ABSTRACT AVAILABLE)
Author(s): vanLoon LJC (REPRINT) ; vanRooijen JJM; Niesen B; Verhagen H; Saris WHM; Wagenmakers AJM

Corporate Source: MAASTRICHT UNIV, DEPT HUMAN BIOL, NUTR & TOXICOL RES INST, NUTRIM, POB 616/NL-6200 MD MAASTRICHT//NETHERLANDS/ (REPRINT); TNO, NUTR & FOOD RES INST, FOOD & SUPPLEMENT ANAL DEPT/NL-3700 AJ ZEIST//NETHERLANDS/

Journal: AMERICAN JOURNAL OF CLINICAL NUTRITION, 2000, V72, N6 (DEC), P 1445-1450

ISSN: 0002-9165 Publication date: 20001200

Publisher: AMER SOC CLINICAL NUTRITION, 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998

Language: English Document Type: ARTICLE

Abstract: Background: (-)-Hydroxycitrate (HCA), a competitive inhibitor of ATP-citrate lyase, should reduce the extramitochondrial acetyl-CoA pool. It has been hypothesized that HCA ingestion can reduce malonyl-CoA concentrations and consequently increase fatty acid oxidation in vivo.

Objective: This study investigated the acute effects of HCA supplementation on substrate utilization at rest and during exercise in endurance-trained humans.

Design: Ten cyclists [(x) over bar +/- SD] age: 24 +/- 2 y, weight: 73 +/- 2 kg, maximal oxygen uptake: 4.95 +/- 0.11 L/min, maximal work output (Wmax): 408 +/- 8 W] were studied at rest and during 2 h of exercise at 50% Wmax on 2 occasions. Both 45 and 15 min before exercise and 30 and 60 min after the start of exercise, 3.1 mL/kg body wt of an HCA solution (19 g/L) or placebo was ingested. Total fat and carbohydrate oxidation rates were assessed. Blood samples were collected at 15-min intervals at rest and every 30 min during exercise.

Results: Plasma HCA concentrations increased after HCA ingestion up to 0.39 +/- 8.02 mmol/L (82.0 +/- 4.8 mg/L). However, no significant differences in total fat and carbohydrate oxidation rates were observed between trials. Accordingly, plasma glucose, glycerol, and fatty acid concentrations did not differ between trials. Plasma lactate concentrations were significantly lower in the HCA than in the placebo trial after 30 min of exercise but at the end of the exercise period they did not differ between trials.

Conclusion: HCA, even when provided in large quantities, does not increase total fat oxidation in vivo in endurance-trained humans.

3/ABKWIC/54 (Item 2 from file: 34)
DIALOG(R) File 34:SciSearch(R) Cited Ref Sci
(c) 2004 Inst for Sci Info. All rts. reserv.

08824838 Genuine Article#: 333CZ Number of References: 23

Title: Managing obesity like any other chronic condition - Long-term therapy may reduce comorbidity as well (ABSTRACT AVAILABLE)

Author(s): Agrawal M; Worzniak M (REPRINT) ; Diamond L

Corporate Source: 18101 OAKWOOD BLVD,/DEARBORN//MI/48111 (REPRINT); OAKWOOD HOSP,/DEARBORN//MI/

Journal: POSTGRADUATE MEDICINE, 2000, V108, N1 (JUL), P75-&

ISSN: 0032-5481 Publication date: 20000700

Publisher: MCGRAW HILL HEALTHCARE PUBLICATIONS, 4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000

Language: English Document Type: ARTICLE

Abstract: Patients often seek help from their primary care physician for weight loss, so familiarity with pharmacologic options and their risks is important. Anorexiant have been available for decades and are relatively safe. Orlistat and sibutramine are two of the newer medications that patients may have heard about in television, newspaper, and magazine advertising. In addition, patients often ask

for advice regarding various herbal or nonprescription medications for weight loss. In this article, the authors help physicians prepare to address these questions.

...Identifiers--PRIMARY PULMONARY-HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; **WEIGHT-LOSS**; **GARCINIA** CAMBOGIA; ORLISTAT; MAINTENANCE; SIBUTRAMINE; INHIBITOR; AGENTS; DRUGS

3/ABKWIC/55 (Item 3 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2004 Inst for Sci Info. All rts. reserv.

07859312 Genuine Article#: 217MW Number of References: 4
Title: **Garcinia** cambogia for **weight loss** - Reply
Author(s): Heymsfield SB (REPRINT) ; Allison DB; Vasselli JR; Pietrobelli A ; Greenfield D; Nunez C
Corporate Source: ST LUKES ROOSEVELT HOSP,/NEW YORK//NY/10025 (REPRINT)
Journal: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, V282, N3 (JUL 21), P235-235
ISSN: 0098-7484 Publication date: 19990721
Publisher: AMER MEDICAL ASSOC, 515 N STATE ST, CHICAGO, IL 60610
Language: English Document Type: LETTER

Title: **Garcinia** cambogia for **weight loss** - Reply

3/ABKWIC/56 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

01194958 1999168630
Garcinia cambogia for **weight loss** [3] (multiple letters)
Badmaev V.; Majeed M.; Conte A.A.; Schaller J.L.; Firenzuoli F.; Gori L.; Heymsfield S.B.; Allison D.B.; Vasselli J.R.; Pietrobelli A.; Greenfield D. ; Nunez C.
ADDRESS: Dr. V. Badmaev, Sabinsa Corporation, Piscataway, NJ, United States
Journal: Journal of the American Medical Association, 282/3 (233-235), 1999 , United States
PUBLICATION DATE: July 21, 1999
CODEN: JAMAA
ISSN: 0098-7484
DOCUMENT TYPE: Letter
LANGUAGES: English

Garcinia cambogia for **weight loss** [3] (multiple letters)

3/ABKWIC/57 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

06450202 EMBASE No: 1996101395
Control of obesity with **Garcinia** cambogia extract
EXTRACTO DE **GARCINIA** CAMBOGIA EN EL CONTROL DE LA OBESIDAD
Roman Ramos R.; Flores Saenz J.; Alarcon Aguilar en M.C.F.
Depto. de Ciencias de la Salud, Div. CBS, UAM,Iztapalapa Mexico
Investigacion Medica Internacional (INVEST. MED. INT.) (Mexico) 1996, 22/3 (97-100)
CODEN: IMEID ISSN: 0185-2108
DOCUMENT TYPE: Journal; Article
LANGUAGE: SPANISH SUMMARY LANGUAGE: SPANISH; ENGLISH

The purpose of the present study was to evaluate the **weight loss** and the decrease of cholesterolemia and triglyceridemia in overweight of subjects treated with lyophilized extract of **Garcinia cambogia** (GC). Two groups were randomly allocated. Each group had 20 adult, healthy (except for the overweight from I to III grade) subjects. Placebo was administered to the subjects in the first group, and GC to the subjects in the second group, both in similar capsules of 500 mg, before each meal and during eight weeks. Results showed that GC caused a significant reduction ($p < 0.05$) of the overweight, cholesterol and triglycerides in relation to the control group with placebo, without the side effects commonly caused by anorectic sympathomimetic amines. In conclusion, it can be assured that GC represents a new efficacious alternative in the control of obesity.

The purpose of the present study was to evaluate the **weight loss** and the decrease of cholesterolemia and triglyceridemia in overweight of subjects treated with lyophilized extract of **Garcinia cambogia** (GC). Two groups were randomly allocated. Each group had 20 adult, healthy (except for...

3/ABKWIC/58 (Item 2 from file: 73)
 DIALOG(R)File 73:EMBASE
 (c) 2004 Elsevier Science B.V. All rts. reserv.

01529721 EMBASE No: 1979251757
 Nephrocystocentesis before surgery as a test of nephrogenic hypertension
 LA NEFROCISTOCENTESI PREOPERATORIA QUALE TEST DI IPERTENSIONE NEFROGENA
 Boccafoschi c.; Muto G.; Mazza G.
 Clin. Urol., Univ. Studi, Trieste Italy
 Urologia (UROLOGIA) (Italy) 1979, 46/2 (151-156)
 CODEN: UROTA
 DOCUMENT TYPE: Journal
 LANGUAGE: ITALIAN

On the basis of a clinical observation concerning blood **hypertension** in a patient with left side renal cyst, investigations were carried out on the possibility to ascertain the clinical connection between the two diseases. In fact, after drawing out 75 ml of **citric** liquid from the cyst of the kidney by cystocentesis, pressure values descended and remained at normal levels during a certain period of time. When the endocystic liquid was formed again, **blood pressure** rose again to high levels, so that surgical removal of the cyst was carried out. Definitive recovery.

On the basis of a clinical observation concerning blood **hypertension** in a patient with left side renal cyst, investigations were carried out on the possibility...

...the clinical connection between the two diseases. In fact, after drawing out 75 ml of **citric** liquid from the cyst of the kidney by cystocentesis, pressure values descended and remained at normal levels during a certain period of time. When the endocystic liquid was formed again, **blood pressure** rose again to high levels, so that surgical removal of the cyst was carried out...

3/ABKWIC/59 (Item 1 from file: 51)
 DIALOG(R)File 51:Food Sci.&Tech.Abs
 (c) 2004 FSTA IFIS Publishing. All rts. reserv.

00761900 1998-06-t0395 SUBFILE: FSTA

Effects of liquid **Garcinia** extract and soluble **Garcinia** powder on body weight change. A possible material for suppressing fat accumulation.

Sawade, H.; Tomi, H.; Tamura, K.; Anno, T.

Food Res. Lab., Nippon Shinyaku Co. Ltd., Nishiohji Hachijo Minami-ku, Kyoto-shi 601, Japan

Journal of the Japan Oil Chemists' Society 1997 , 46 (12) 1467-1474

LANGUAGE: Japanese SUMMARY LANGUAGE: English

Garcinia is a fruit which has been found to be effective in **reducing** body wt., hydroxycitric acid (HCA) being its active principle. **Garcinia** powders can be prepared with HCA in the form of a calcium salt, however this is not ideal for food products due to the insolubility of the Ca form in water. A soluble **Garcinia** powder and a liquid **Garcinia** extract were prepared containing HCA in the lactone form and their effects on wt. change were compared with those of Ca type powders in rats and humans. Soluble **Garcinia** powder was found to be more effective for wt. **reduction** than the Ca type

Garcinia powder in rats. It is concluded that soluble **Garcinia** powder and liquid **Garcinia** extract may be effective in **reducing** human body wt. by decreasing fat accumulation. (From En summ.)

Garcinia is a fruit which has been found to be effective in **reducing** body wt., hydroxycitric acid (HCA) being its active principle. **Garcinia** powders can be prepared with HCA in the form of a calcium salt, however this...

...for food products due to the insolubility of the Ca form in water. A soluble **Garcinia** powder and a liquid **Garcinia** extract were prepared containing HCA in the lactone form and their effects on wt. change were compared with those of Ca type powders in rats and humans. Soluble **Garcinia** powder was found to be more effective for wt. **reduction** than the Ca type **Garcinia** powder in rats. It is concluded that soluble **Garcinia** powder and liquid **Garcinia** extract may be effective in **reducing** human body wt. by decreasing fat accumulation. (From En summ.)

3/ABKWIC/60 (Item 2 from file: 51)

DIALOG(R) File 51:Food Sci.&Tech.Abs

(c) 2004 FSTA IFIS Publishing. All rts. reserv.

00756541 1998-03-t0200 SUBFILE: FSTA

The spice of life?

Anon.

Food Ingredients and Analysis International 1997 , 19 (Nov./Dec.)

45-46, 49

LANGUAGE: English

Dried fruits of **Garcinia** cambogia, also called Malabar tamarind, are widely used as a spice in the preparation of fish curry in southern India. Its use as a metabolic regulator of obesity and its potential as a functional food are discussed. Aspects considered are: description of **Garcinia** cambogia; manufacturing process; metabolism; product formulation; use of **Garcinia** extract (and its main constituent hydroxycitric acid) for obesity **control**; and recommended daily intake for wt. management.

Dried fruits of **Garcinia** cambogia, also called Malabar tamarind, are widely used as a spice in the preparation of...

...obesity and its potential as a functional food are discussed. Aspects considered are: description of **Garcinia** cambogia; manufacturing process; metabolism; product formulation; use of **Garcinia** extract (and its main constituent hydroxycitric acid) for obesity **control**;

and recommended daily intake for wt. management.

3/ABKWIC/61 (Item 1 from file: 351)
 DIALOG(R)File 351:Derwent WPI
 (c) 2004 Thomson Derwent. All rts. reserv.

013657895

WPI Acc No: 2001-142107/200115

XRAM Acc No: C01-042581

Diet dish for preventing obesity, comprises extract of Garcinia as an active ingredient

Patent Assignee: TOKIWA YAKUHHIN KOGYO KK (TOKI-N)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 2000333640	A	20001205	JP 99146030	A	19990526	200115 B

Priority Applications (No Type Date): JP 99146030 A 19990526

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
JP 2000333640	A	5	A23L-001/30	

Abstract (Basic): JP 2000333640 A

Abstract (Basic):

NOVELTY - A daily diet dish comprises an extract of Garcinia as active ingredient, mixed with other ingredients.

USE - As diet foodstuff for preventing obesity.

ADVANTAGE - The dish effectively inhibits accumulation and synthesis of fat and hence enhances slimming effect. The dish provides low calories and thereby prevents the various illnesses caused by increased intake of high calorie food. The chicken extract blended with the daily dish accelerates the synthesis and combustion of fat in the body, improves diet and also increases the taste of the dish.

pp; 5 DwgNo 1/0

3/ABKWIC/62 (Item 2 from file: 351)
 DIALOG(R)File 351:Derwent WPI
 (c) 2004 Thomson Derwent. All rts. reserv.

013099310

WPI Acc No: 2000-271182/200023

XRAM Acc No: C00-082693

Hydroxycitric acid composition, useful as anorectic agent, comprising partial calcium salt of hydroxycitric acid, is water soluble, non-hygroscopic, and pleasant tasting

Patent Assignee: INTERHEALTH NUTRACEUTICALS INC (INTE-N)

Inventor: GOKARAJU G R

Number of Countries: 021 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200015051	A1	20000323	WO 99US21099	A	19990914	200023 B

Priority Applications (No Type Date): US 98151806 A 19980914

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
WO 200015051	A1 E	23	A23L-001/30	

Designated States (National): CA IN JP

Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LU

MC NL PT SE

Abstract (Basic): WO 200015051 A1

Abstract (Basic):

NOVELTY - Hydroxycitric acid (HCA) compositions, useful as dietary supplements for inhibiting lipogenesis, promoting **weight loss** and suppressing appetite, have an increased wt. % HCA, are water soluble, non-hygroscopic and pleasant tasting. They comprise a HCA partially converted to a calcium salt, are potassium free and are prepared from an extract of **Garcinia** sp.

ACTIVITY - Anorectic agent; appetite suppressant.

MECHANISM OF ACTION - Inhibitor of lipogenesis.

USE - For inhibiting lipogenesis, promoting weight loss and/or suppressing appetite (all claimed).

ADVANTAGE - The composition has a pleasant taste, is water soluble and non-hygroscopic, and contains a higher wt.% (up to 65) of hydroxycitric acid (HCA) than e.g. CITRIMAX (RTM) which has a maximum of 60 wt.%.

pp; 23 DwgNo 0/0

Abstract (Basic):

... Hydroxycitric acid (HCA) compositions, useful as dietary supplements for inhibiting lipogenesis, promoting **weight loss** and suppressing appetite, have an increased wt. % HCA, are water soluble, non-hygroscopic and pleasant...

...converted to a calcium salt, are potassium free and are prepared from an extract of **Garcinia** sp.

3/ABKWIC/63 (Item 3 from file: 351)
DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

011538605

WPI Acc No: 1997-515086/199748

XRAM Acc No: C97-164618

Diet preparations with anti-hypercholesterolaemic and anti-cholesterolaemic activities - contain chitosan, **Garcinia** cambogia extract and chromium, used as diet integrator in **weight-reducing** programs aimed at calorie restrictions in obese patients

Patent Assignee: SIRC NATURAL & DIETETIC FOODS SPA (SIRC-N)

Inventor: LITTERA R

Number of Countries: 023 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 803202	A2	19971029	EP 97830189	A	19970424	199748 B
IT 1284636	B	19980521	IT 96RM279	A	19960426	200010

Priority Applications (No Type Date): IT 96RM279 A 19960426

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 803202	A2	E	6	A23L-001/30	

Designated States (Regional): AL AT BE CH DE DK ES FI FR GB GR IE IT LI
LT LU LV MC NL PT RO SE SI

IT 1284636 B A61K-000/00

Abstract (Basic): EP 803202 A

Use of chitosan in combination with **Garcinia** cambogia extracts and chromium in dietary preparations for reducing total cholesterol, LDL cholesterol, triglycerides and/or body weight, and for increasing cholesterol is new.

USE - The preparations have antihyperlipoproteinaemic and anticholesterolaemic activities (claimed). Preparations are used as a diet integrator in weight-reducing programs aimed at calorie

restrictions in obese patients, in the treatment of hypertension and as a hypocholesterolaemic product.

Dwg.0/0

... contain chitosan, **Garcinia** cambogia extract and chromium, used as diet integrator in **weight-reducing** programs aimed at calorie restrictions in obese patients

? ? □

? DS

Set	Items	Description
S1	168	(CITRIN OR GARCIN?) (S) (HYPERTEN? OR ANTIHYPERTEN? OR (BLD - OR BLOOD) (W) PRESSURE OR (WEIGHT OR WT) (5N) (CONTROL OR REDUC? - OR LOSS))
S2	111	RD (unique items)
S3	63	S2 NOT (PY=2004 OR PY=2003 OR PY=2002 OR PY=2001)
S4	1296	HYDROXYCITR?
S5	25	S4 AND (HYPERTEN? OR (BLOOD OR BLD) (W) PRESSURE)
S6	21	RD (unique items)
S7	21	S6 NOT S3
?		
?		
?		T S7/3 AB/1-21

7/AB/1 (Item 1 from file: 5)
 DIALOG(R) File 5: Biosis Previews(R)
 (c) 2004 BIOSIS. All rts. reserv.

0014615015 BIOSIS NO.: 200300583734

Effects of niacin-bound chromium, Maitake mushroom fraction SX and (-)-**hydroxycitric** acid on the metabolic syndrome in aged diabetic Zucker fatty rats.

AUTHOR: Talpur Nadeem; Echard Bobby W; Yasmin Taharat; Bagchi Debasis; Preuss Harry G (Reprint)

AUTHOR ADDRESS: Department of Physiology and Biophysics, Georgetown University Medical Center, 3900 Reservoir Road, N. W., Basic Science Building, Room 231B, Washington, D.C., 20057, USA**USA

AUTHOR E-MAIL ADDRESS: preussbh@georgetown.edu

JOURNAL: Molecular and Cellular Biochemistry 252 (1-2): p369-377 October 2003 2003

MEDIUM: print

ISSN: 0300-8177 (ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Previous studies in our laboratories have demonstrated that niacin-bound chromium (NBC), Maitake mushroom and (-)-**hydroxycitric** acid (HCA-SX) can ameliorate **hypertension**, dyslipidemias and diabetes mellitus, and therefore may be useful in weight management. In the present study, we used aged, diabetic Zucker fatty rats (ZFR) (70-75 weeks) in order to determine whether NBC, fraction SX of Maitake mushroom (MSX) and 60% (-)-**hydroxycitric** acid (HCA-SX) from *Garcinia* cambogia, alone or in combination, can affect certain aspects of the metabolic syndrome. Syndrome X or metabolic syndrome has been described as a concurrence of disturbed glucose and insulin metabolism, overweight and abdominal fat distribution, mild dyslipidemia, and **hypertension**, which are associated with subsequent development of type 2 diabetes mellitus and cardiovascular disease. Four groups of eight ZFR were gavaged daily with different supplements. For the initial three weeks, the control group of ZFR received only water, the second group received

NBC 40 mcg elemental chromium/day, the third group received MSX 100 mg/day and the last group received HCA-SX 200 mg/day. During weeks 4-6, the doses of each treatment were doubled. The control animals lost approximately 50 g body weight (BW) per rat over 6 weeks of treatment, which is characteristic of these animals in declining health. In contrast, eight ZFR receiving NBC lost approximately 9 g BW per rat, while rats consuming MSX lost 16 g BW per rat. However, ZFR receiving HCA-SX simulated the pattern in the control group because these animals lost approximately 46 g BW per rat. The wide individual variations resulted in a lack of statistical significance among groups. Nevertheless, 75% of the ZFR in the control group lost more than 50 g BW over the 6 weeks duration, whereas none of the ZFR receiving NBC, 25% of the ZFR receiving MSX and 57% of the ZFR receiving HCA-SX lost over 50 g BW over the 6 weeks of the study. ZFR in all 3 treatment groups showed significantly lower blood pressures as compared to control, which seemed to be dose related. The general trend was for renal and liver blood parameters, hepatic and renal lipid peroxidation and DNA fragmentation to improve due to the supplementation of these natural products. Treatment of animals with a combination of these three novel supplements resulted in a lower SBP and maintenance of BW compared to control animals. These results demonstrate that elderly diabetics and even aging individuals might benefit from a similar regimen.

7/AB/2 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2004 The Dialog Corp. All rts. reserv.

17247936 PMID: 15544444

A perspective on the current strategies for the treatment of obesity.
 Joyal Steven V
 Global Clinical Research, Pharmaceutical Research Institute,
 Bristol-Myers Squibb, Princeton, New Jersey, USA. steven.joyal@bms.com.
 Current drug targets. CNS and neurological disorders (Netherlands) Oct
 2004, 3 (5) p341-56, ISSN 1568-007X Journal Code: 101151150
 Document type: Journal Article
 Languages: ENGLISH
 Main Citation Owner: NLM
 Record type: In Data Review

The prevalence in obesity has increased dramatically over the past 30 years, more than double in the United States alone. Obesity is associated with an increased risk for type 2 diabetes mellitus, dyslipidemia, **hypertension**, biliary disease, obstructive sleep apnea, and certain types of cancer. The pathophysiology of obesity is complex, involving behavioral, environmental, and genetic factors. Current treatment options include behavior modification and lifestyle changes which incorporate weight-reducing diets and physical activity, FDA approved long-term anti-obesity pharmacological agents sibutramine and orlistat, non-FDA approved over-the-counter (OTC) supplements and nutraceuticals, and, when appropriate, bariatric surgery. Without adequate prevention and treatment of obesity, government agencies have suggested that the direct and indirect costs associated with obesity may overwhelm the healthcare system. This brief review explores the current data available on treatments for the obese patient including the relative merits of different types of macronutrient composition (e.g., low carbohydrate vs. high carbohydrate diets) of weight-reducing diets, the value of resistance/ strength training in physical activity programs designed for the obese patient, the safety and efficacy associated with OTC supplements and nutraceuticals for weight reduction (e.g., Ephedra, conjugated linoleic acid (CLA), Garcinia cambogia/ **hydroxycitric** acid (HCA), chromium, pyruvate), the safety and efficacy of FDA-approved long-term obesity treatments sibutramine and orlistat, and bariatric surgery.

7/AB/3 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

07772154 PMID: 3368856
[Treatment of patients with food toxoinfections in middle and old age]
Lechenie bol'nykh s pishchevymi toksikoinfektsiiami v pozhilom i
starcheskom vozraste.
Bro dov L E; Maleev V V; Chekalina K I; Bogin I B
Terapevticheskii arkhiv (USSR) 1988, 60 (2) p132-4, ISSN 0040-3660
Journal Code: 2984818R
Document type: Journal Article ; English Abstract
Languages: RUSSIAN
Main Citation Owner: NLM
Record type: Completed
Altogether 320 elderly and old-aged patients with alimentary
toxoinfections suffering from essential **hypertension** (65.9%), coronary
heart disease (39.3%), atherosclerosis (29.3%) were observed. A severe
course of toxoinfection was noted in 5.9% of the patients, an average severe
course in 94.1%. The patients received intravenously the "quartasol"
solution in full volume (25.7%) or the ORS solution with sodium
hydroxycitrate per os (74.3%). Therapeutic efficacy was high.
Antihypertensive therapy and antianginal drugs were simultaneously
administered. Neither complications nor side effects were observed during
therapy of the elderly and old-aged patients with alimentary toxoinfections.
In addition to the above therapy all the patients received sparing diet and
enzyme preparations.

7/AB/4 (Item 1 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

10988357 Supplier Number: 112864451
Clinical Study on Ephedra-Free Super CitriMax Published in Nutrition
Research; New Health Benefits -- Beyond Weight Loss -- Also Discovered.
Business Wire, p5389
Feb 3, 2004
Language: English Record Type: Fulltext
Document Type: Newswire; Trade
Word Count: 1221

7/AB/5 (Item 2 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

10432742 Supplier Number: 96057437
Real help for weight loss. (In The Raw Spotlight).
Railing, Cindy
Health Products Business, v48, n11, p42(1)
Dec, 2002
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Trade
Word Count: 709

7/AB/6 (Item 3 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

10432709 Supplier Number: 96057404
Help your customers say goodbye to holiday weight gain.
Bushkin, Gary; Bushkin, Estitta
Health Products Business, v48, n11, p18(3)
Dec, 2002
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Trade
Word Count: 2670

7/AB/7 (Item 4 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

10282057 Supplier Number: 98252290
Cardio health: the latest research on cardiovascular ingredients and
products. (Getting to the Heart of).
Gormley, James J.
Health Products Business, v49, n2, p13(3)
Feb, 2003
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Trade
Word Count: 2143

7/AB/8 (Item 5 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

10120270 Supplier Number: 91821607
Natural weight loss options. (Formulating of Wellness).(Brief Article)
Gupta, Tony; O'Donnell, Claudia D.
Prepared Foods, v171, n9, pNS2(3)
Sept, 2002
Language: English Record Type: Fulltext
Article Type: Brief Article
Document Type: Magazine/Journal; Trade
Word Count: 1265

7/AB/9 (Item 6 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

09208924 Supplier Number: 79260973
Weight Loss, Diets, and Supplements: Does Anything Work?
Boucher, Jackie L.; Shafer, Kimberly J.; Chaffin, Jodi A.
Diabetes Spectrum, v14, n3, p169
Summer, 2001
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Professional
Word Count: 4069

7/AB/10 (Item 7 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

08794561 Supplier Number: 76495868
Nutritional Supplements Are Under the Weather.(sales decline)(Statistical
Data Included)

Kane, Janice Roma
Chemical Market Reporter, v260, n26, pFR 18
June 25, 2001
Language: English Record Type: Fulltext
Article Type: Statistical Data Included
Document Type: Magazine/Journal; Trade
Word Count: 2116

7/AB/11 (Item 8 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2004 The Gale Group. All rts. reserv.

08755942 Supplier Number: 75958608
SPORTS AND WEIGHT LOSS SUPPLEMENTS: A WINNING TEAM.
Bushkin, Gary; Bushkin, Estitta
Health Products Business, v47, n6, p38
June, 2001
Language: English Record Type: Fulltext
Document Type: Magazine/Journal; Trade
Word Count: 2936

7/AB/12 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2004 Inst for Sci Info. All rts. reserv.

04028794 Genuine Article#: QZ482 Number of References: 130
Title: REDUCTION OF FREE FATTY-ACIDS MAY AMELIORATE RISK-FACTORS ASSOCIATED
WITH ABDOMINAL OBESITY (Abstract Available)
Author(s): MCCARTY MF
Corporate Source: NUTR 21,1010 TURQUOISE ST,SUITE 35/SAN DIEGO//CA/92109
Journal: MEDICAL HYPOTHESES, 1995, V44, N4 (APR), P278-286
ISSN: 0306-9877
Language: ENGLISH Document Type: REVIEW
Abstract: Experimental data as well as logical considerations suggest that
the increased cardiovascular risk associated with abdominal obesity is
mediated primarily by increased levels and flux of free fatty acids.
Practical strategies for decreasing free fatty acid levels and/or flux
may include: a very-low-fat, low-glycemic-index diet; promotion of
insulin sensitivity (via exercise training, chromium, soluble fiber or
drugs); anti-lipolytic agents; and stimulation of hepatic lipid
oxidation with **hydroxycitrate**, carnitine and possibly fish
omega-3s. Fortunately, many of these measures should also promote a
leaner physique. Thus, even when abdominal obesity cannot be corrected,
it may prove feasible to mitigate its dangers.

7/AB/13 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

12155798 EMBASE No: 2003264089
Herbal preparations for obesity: Are they useful?
Heber D.
Dr. D. Heber, UCLA Center for Human Nutrition, University of California,
900 Veteran Avenue, Los Angeles, CA 90095-1742 United States
AUTHOR EMAIL: dheber@mednet.ucla.edu
Primary Care - Clinics in Office Practice (PRIM. CARE CLIN. OFF. PRACT.
) (United States) 2003, 30/2 (441-463)
CODEN: PRCAD ISSN: 0095-4543
DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 118

The opportunities for additional research in this area are plentiful. Unfortunately, there has been relatively limited funding for research on herbal supplements compared with the amount of funding that is available for research on pharmaceuticals. Botanical dietary supplements often contain complex mixtures of phytochemicals that have additive or synergistic interactions. For example, the tea catechins include a group of related compounds with effects that are demonstrable beyond those that are seen with epigallocatechin gallate, the most potent catechin. The metabolism of families of related compounds may be different than the metabolism of purified crystallized compounds. In some cases, herbal medicines may simply be less purified forms of single active ingredients, but in other cases they represent unique formulations of multiple, related compounds that may have superior safety and efficacy compared with single ingredients. Obesity is a global epidemic, and traditional herbal medicines may have more acceptance than prescription drugs in many cultures with emerging epidemics of obesity. Several ethnobotanical studies found herbal treatments for diabetes, and similar surveys, termed bioprospecting, for obesity treatments may be productive. Beyond increasing thermogenesis, there are other biological rationales for the actions of several different alternative medical and herbal approaches to weight loss. For example, several supplements and herbs claim to result in nutrient partitioning so that ingested calories will be directed to muscle, rather than fat. These include an herb (*Garcinia cambogia*), and a lipid which is the product of bacterial metabolism (conjugated linoleic acid). Moreover, a series of approaches attempt to physically affect gastric satiety by filling the stomach. Fiber swells after ingestion and has been found to result in increased satiety. A binding resin (Chitosan) has the ability to precipitate fat in the laboratory and is touted for its ability to bind fat in the intestines so that it is not absorbed. In double-blind studies, however, this approach was found to be ineffective. There are two key attractions of alternative treatments to obese patients. First, they are viewed as being natural and are assumed by patients to be safer than prescription drugs. Second, there is no perceived need for professional assistance with these approaches. For obese individuals who cannot afford to see a physician, these approaches often represent a more accessible solution. Finally, for many others, these approaches represent alternatives to failed attempts at weight loss with the use of more conventional approaches. These consumers are often discouraged by previous failures, and are likely to combine approaches or use these supplements at doses higher than are recommended. It is vital that the primary care physician is aware of the herbal preparations that are being used by patients so that any potential interaction with prescription drugs or underlying medical conditions can be anticipated. Unfortunately, there have been several instances where unscrupulous profiteers have plundered the resources of the obese public. Although Americans spend \$30 billion per year on weight loss aids, our regulatory and monitoring capability as a society are woefully inadequate. Without adequate resources, the FDA resorted to "guilt by association" adverse events reporting, which often results in the loss of potentially helpful therapies without adequate investigation of the real causes of the adverse events that are reported. Scientific investigations of herbal and alternative therapies represent a potentially important source for new discoveries in obesity treatment and prevention. Cooperative interactions in research between the Office of Dietary Supplements, the National Center for Complementary and Alternative Medicine, and the FDA could lead to major advances in research on the efficacy and safety of the most promising of these alternative approaches.

DIALOG(R)File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

11052944 EMBASE No: 2000400228

A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin

Thom E.

Dr. E. Thom, Parexel Medstat AS, PO Box 210, N-2001 Lillestrom Norway

AUTHOR EMAIL: erling.thom@parexel.com

Journal of International Medical Research (J. INT. MED. RES.) (United Kingdom) 2000, 28/5 (229-233)

CODEN: JIMRB ISSN: 0300-0605

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 13

The efficacy and tolerability of a new weight-reduction agent, based on natural ingredients, was investigated in this randomized, placebo-controlled, double-blind study. The product reduces the absorption of different types of sugar from the gastrointestinal tract. Forty obese volunteers were included in the 12-week study. Body weight, body composition and **blood pressure** were recorded at baseline and every month during the study. The results show a significant difference in weight reduction in favour of the active group (3.5 kg versus 1.2 kg). Body composition measurements showed that > 85% of the reduction in the active group is fat loss. The tolerability was similar and good in both groups. This product shows promising results and should be studied more extensively at different dose levels.

7/AB/15 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2004 Elsevier Science B.V. All rts. reserv.

10817278 EMBASE No: 2000298826

Current and potential drugs for treatment of obesity

Bray G.A.; Greenway F.L.

Dr. G.A. Bray, 6400 Perkins Road, Baton Rouge, LA 70808 United States

Endocrine Reviews (ENDOCR. REV.) (United States) 1999, 20/6 (805-875)

CODEN: ERVID ISSN: 0163-769X

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 999

7/AB/16 (Item 1 from file: 351)

DIALOG(R)File 351:Derwent WPI

(c) 2004 Thomson Derwent. All rts. reserv.

016110091

WPI Acc No: 2004-267967/200425

Related WPI Acc No: 2003-102288

XRAM Acc No: C04-104361

Metabolic uncoupling therapy involves formulating a combination of agent of metabolic uncoupling therapy that limits the accumulation of high-energy electrons potentially available to the electron transport chain

Patent Assignee: MCCLEARY E L (MCCL-I)

Inventor: MCCLEARY E L

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
-----------	------	------	-------------	------	------	------

US 20040043013 A1 20040304 US 2000749584 A 20001228 200425 B
US 2003462958 A 20030617

Priority Applications (No Type Date): US 2003462958 A 20030617; US
2000749584 A 20001228

Patent Details:

Patent No	Kind	Ln	Pg	Main IPC	Filing Notes
US 20040043013	A1	21	A61K-031/7076	CIP of application	US 2000749584
				CIP of patent	US 6579866

Abstract (Basic): US 20040043013 A1

Abstract (Basic):

NOVELTY - Metabolic uncoupling therapy (MUT) involves analyzing specific physiologic process, including delineating the metabolic pathways related to reductive stress; identifying several MUT agents that modulate the metabolic pathways by influencing electron flux; and formulating combination of MUT agent that limits the accumulation of high-energy electrons potentially available to the electron transport chain.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition comprising at least two (preferably at least three, especially at least five) small electrophilic biomolecules (a), at least one oxaloacetate precursor (b), at least two vitamin B and its structurally related entity (c) (preferably at least three, especially at least five); and at least one electron cycling agent (d). (a) Is TMG (trimethylglycine), choline, phosphatidyl choline, SAME (S-adenosyl methionine), carnitine, ALC (acetyl L-carnitine), propionyl carnitine, myoinositol, sphingomyelin, glycerylphosphorylcholine or acetylcholine. (b) Is pyruvate, aspartate, glycine or serine. (c) Is folate, riboflavin, B1, B3, niacinamide, nicotinamide, polynicotinate, B6, B12, biotin, pantothenic acid, riboflavin or related chemical species. (d) Is coenzyme Q10, lipoic acid or acetoacetate.

ACTIVITY - Antidiabetic; Antilipemic; Antiinflammatory; Vasotropic; Cardiant; Cerebroprotective; Anorectic; Nootropic; Tranquilizer; Muscular-Gen.; Dermatological; Neuroprotective; Gastrointestinal-Gen.; Hepatotropic; Virucide. Test details are given, but no results are given.

MECHANISM OF ACTION - None given.

USE - For metabolite uncoupling therapy (claimed), which is useful for the prevention of a multitude of conditions and as a therapeutic modality under conditions of disease e.g. high **blood pressure**, diabetes, dyslipidemia, hyperlipidemia, hypercholesterolemia, insulin resistance, inflammation, vascular disease, heart disease, stroke, overweight, obesity, neuronal and/or cognitive dysfunction, dementia, attention and attention/hyperactivity disorder, mood disorder, muscular damage, muscular deterioration or soreness, athletic compromise, sarcopenia, glucose intolerance and other disorders of glucose metabolism, premature aging, skin deterioration and/or damage either associated with, or not associated with sun exposure, loss of muscle tone, frailty and bone loss, and aging. The composition is useful in food products e.g. milk or milk products, juices, shakes, salad dressing, gravies, sauces, nutritional bars, protein powders and any other palatable food products and in enhancement of athletic performance in greyhounds or racehorses, enhanced and prolonged fertility in breeding stock and health maintenance in household pets and as a brain performance-enhancing drink mix. For the treatment of neurodegenerative disorders e.g. multiple sclerosis and Alzheimer's disease, inflammatory gastrointestinal disorder and hepatic steatosis/steatohepatitis.

ADVANTAGE - The combination of the MUT agents limits the accumulation of high-energy electrons potentially available to the electron transport chain. The MUT includes manipulation of flux of

high-energy electrons through biochemical pathways; modulation of related cell processes and signaling systems, modulation of metabolic intermediates involved in the production of high energy electrons and modulation of nucleotides, nucleotide ratios and nucleotide cycling. The MUT minimizes adverse side effects that might occur through inappropriate usage of various compound and composition not in accordance with the combination of the MUT agents.

pp; 21 DwgNo 0/0

7/AB/17 (Item 2 from file: 351)
DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

015536019

WPI Acc No: 2003-598169/200356

Related WPI Acc No: 2002-750629

XRAM Acc No: C03-162246

Pharmaceutical composition, useful for the promotion of healthy body weight, and to reduce the risk of obesity related ailments e.g.

hypertension, type II diabetes or arthritis, comprises

hydroxycitric acid

Patent Assignee: INTERHEALTH NUTRACEUTICALS (INTE-N); INTERHEALTH NUTRACEUTICALS INC (INTE-N); BAGCHI D (BAGC-I); PREUSS H G (PREU-I)

Inventor: BAGCHI D; PREUSS H G

Number of Countries: 101 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200353454	A1	20030703	WO 2002US41171	A	20021220	200356 B
US 20040014692	A1	20040122	US 2001343473	P	20011220	200407
			US 2002325675	A	20021220	
AU 2002364213	A1	20030709	AU 2002364213	A	20021220	200428
EP 1461051	A1	20040929	EP 2002799288	A	20021220	200463
			WO 2002US41171	A	20021220	

Priority Applications (No Type Date): US 2001343473 P 20011220; US 2002325675 A 20021220

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200353454 A1 E 17 A61K-033/24

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

Designated States (Regional): ATBE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW

US 20040014692 A1 A61K-031/704 Provisional application US 2001343473

AU 2002364213 A1 A61K-033/24 Based on patent WO 200353454

EP 1461051 A1 E A61K-033/24 Based on patent WO 200353454

Designated States (Regional): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR

Abstract (Basic): WO 200353454 A1

Abstract (Basic):

NOVELTY - Increase of a serotonin level involves administration of a composition (C1) comprising **hydroxycitric acid** (HCA).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition (C2) comprising **hydroxycitric acid**, chromium and gymnemic acid.

ACTIVITY - Antilipemic; Anorectic; Antiarthritic; Hypotensive;

Antidiabetic; Cytostatic.

The antilipemic and anorectic activity was evaluated in individuals by administering a placebo (control), a daily dose of Garcinia cambogia extract (4667 mg) (test 1) and a combination of HCA-SX Super CitriMax (RTM; **hydroxycitric** acid composition) and ChromeMate (RTM; HCA-SX, chromium and gymnemic acid composition) (test 2) in three equally divided doses for 30-60 minutes before breakfast for 8 weeks. The (%) changes obtained for control/test 1/test 2, respectively, were:

- (1) body weight=1.9/5.0/6.5;
- (2) LDL cholesterol=2.8/-13.0/-19.0; and
- (3) food intake reduction=0/11.4/17.2.

MECHANISM OF ACTION - Serotonin release stimulator; Serotonin release uptake inhibitor; Lipogenesis inhibitor; Fat synthesis inhibitor; Obesity gene down regulator.

USE - The composition is useful for reducing excess/maintaining healthy body weight or body mass index. It also serves to suppress appetite and/or lead to a reduction in food intake. Furthermore, the composition is useful for decreasing total cholesterol, LDL cholesterol and/or triglyceride levels (all claimed) and obesity gene level. By the promotion of healthy body weight, obesity associated ailments such as arthritis, **hypertension**, type II diabetes, elevated cholesterol and cancer can be prevented.

ADVANTAGE - The composition improves physiological factors including serum serotonin level, serum leptin level, fat oxidation, cholesterol level and body mass index. HCA increases serum leptin level, thus down regulating the genetic propensity toward obesity. HCA produces its effect without stimulating the central nervous system. The composition provides enhanced biochemical induction of glycerol kinase, which can serve to enhance two important biochemical functions such as biochemical reduction of triglyceride levels and fat oxidation.

pp; 17 DwgNo 0/0

7/AB/18 (Item 3 from file: 351)
 DIALOG(R) File 351:Derwent WPI
 (c) 2004 Thomson Derwent. All rts. reserv.

015431089

WPI Acc No: 2003-493231/200346

XRAM Acc No: C03-132027

Preventing or reducing symptoms of insulin resistance leading to increased risk of e.g. diabetes, obesity and heart disease, comprises administering composition containing niacin bound chromium

Patent Assignee: INTERHEALTH NUTRACEUTICALS INC (INTE-N); BAGCHI D (BAGC-I); KOTHARI S C (KOTH-I); PREUSS H G (PREU-I)

Inventor: BAGCHI D; KOTHARI S C; PREUSS H G

Number of Countries: 101 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200339535	A1	20030515	WO 2002US31987	A	20021007	200346 B
US 20030133992	A1	20030717	US 2001327896	P	20011005	200348
			US 2002265093	A	20021004	
EP 1438038	A1	20040721	EP 2002786372	A	20021007	200447
			WO 2002US31987	A	20021007	
AU 2002351456	A1	20030519	AU 2002351456	A	20021007	200464

Priority Applications (No Type Date): US 2001327896 P 20011005; US 2002265093 A 20021004

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 200339535	A1	E	8	A61K-031/28	

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA
CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ
OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA
ZM ZW

Designated States (Regional): AT BE BG CH CY CZ DE DK EA EE ES FI FR GB
GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
US 20030133992 A1 A61K-033/32 Provisional application US 2001327896

EP 1438038 A1 E A61K-031/28 Based on patent WO 200339535
Designated States (Regional): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
AU 2002351456 A1 A61K-031/28 Based on patent WO 200339535

Abstract (Basic): WO 200339535 A1

Abstract (Basic):

NOVELTY - Preventing or reducing symptoms of insulin resistance
comprises administering a composition comprising niacin bound chromium
(I).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a
composition which comprises (I) and three compounds selected from (-)
hydroxycitric acid, zinc, trans-resveratrol, gymnemic acid,
selenium, anthocyanidin, allicin and saponin.

ACTIVITY - Antidiabetic; Anorectic; Cardiant; Antiartherosclerotic;
Hypotensive.

In a test, one half of a group (test) of 100 normotensive rats were
fed a diet containing Chrome Mate (chromium nicotinate) at a human
equivalency dosage of 400 mug, Opti Zinc (zinc methionine) and Acti vin
(grape seed extract incorporating proanthocyanidins). The test rats had
lowered **blood pressure** and lipid peroxidation in their
livers and kidneys compared to control rats (with normal diet). In test
rats, sugar-induced **hypertension** was also reduced along with
hepatic and renal lipid peroxidation and glycosylated hemoglobin
levels.

MECHANISM OF ACTION - None given.

USE - Used for preventing or reducing symptoms of insulin
resistance resulting in elevating body insulin levels, which leads to
increased risk of diabetes, obesity, heart disease, atherosclerosis,
cardiovascular disease, impaired glucose tolerance, hyperinsulinemia,
hyperglyceridemia, elevated low density cholesterol, low high density
lipoprotein (HDL) cholesterol and **hypertension**.

ADVANTAGE - The method reduces symptoms of syndrome X.
pp; 8 DwgNo 0/0

7/AB/19 (Item 4 from file: 351)
DIALOG(R)File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

015121603

WPI Acc No: 2003-182126/200318

XRAM Acc No: C03-047883

Use of (-)-**hydroxycitric acid** for treating and ameliorating
polymorphic metabolic dysfunction

Patent Assignee: CLOUATRE D L (CLOU-I); DUNN J M (DUNN-I)

Inventor: CLOUATRE D L; DUNN J M

Number of Countries: 001 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 6476071	B1	20021105	US 2001850280	A	20010507	200318 B
US 20020193430	A1	20021219	US 2001850280	A	20010507	200318

Priority Applications (No Type Date): US 2001850280 A 20010507

Patent Details:

Patent No	Kind	Lan	Pg	Main	IPC	Filing	Notes
US 6476071	B1		16	A01N-037/00			
US 20020193430	A1			A61K-031/366			

Abstract (Basic): US 6476071 B1

Abstract (Basic):

NOVELTY - Treating and ameliorating polymorphic metabolic dysfunction (PMD) involves administration of (-)-**hydroxycitric** acid (A). PMD is characterized by glucocorticoid metabolism dysregulation. (A) influences the regulation of glucocorticoid metabolism of leptin, resistin or peroxisome proliferator-activated receptor-gamma (PPAR-gamma).

ACTIVITY - Antilipemic; Anorectic.

An open clinical weight loss trial with extremely obese patients was undertaken to gauge the effects of a pouch delivery form of a potassium salt of (-)-**hydroxycitrate** acid (HCA). The patients were enrolled with diabetes and these suspected of suffering from insulin resistance. The patients were administered HCA (3-4 g/day) in 2 doses. The patients experienced good appetite suppression. The average weight loss over the 3 week period for the patients were 3.1 pounds per person. HCA also showed an ability to normalize **blood pressure**.

MECHANISM OF ACTION - PMD regulator; Blood lipid inducer; Weight loss inducer.

USE - For treating and ameliorating polymorphic metabolic dysfunction, elevated glucocorticoid levels, leptin levels and leptin resistance, resistin levels and proliferative-activated receptor-gamma activity (all claimed). Also reduces blood lipids, induces weight loss and decrease appetite.

ADVANTAGE - (A) Influences the regulation of glucocorticoid metabolism of leptin, resistin or peroxisome proliferator-activated receptor-gamma (PPAR-gamma). The regulation of PMD over any given period of time may be improved with a controlled release form of (A). (A) Has a multitude of metabolic functions and reduces blood lipids, induces weight loss and decrease appetite in both animals and humans.
pp; 16 DwgNo 0/4

7/AB/20 (Item 5 from file: 351)

DIALOG(R) File 351:Derwent WPI

(c) 2004 Thomson Derwent. All rts. reserv.

014530883

WPI Acc No: 2002-351586/200238

XRAM Acc No: C02-099819

Weight loss therapy by appetite suppression, increasing lean body mass involves use of **hydroxycitric** acid or forskolin in combination with garcinol and/or anthocyanin

Patent Assignee: SABINSA CORP (SABI-N); HADMAEV V (HADM-I); MAJEED M (MAJE-I)

Inventor: BADMAEV V; MAJEED M; HADMAEV V

Number of Countries: 097 Number of Patents: 006

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200214477	A2	20020221	WO 2001US41748	A	20010817	200238 B
AU 200196851	A	20020225	AU 200196851	A	20010817	200245
EP 1254209	A2	20021106	EP 2001977759	A	20010817	200281
			WO 2001US41748	A	20010817	
US 20020187943	A1	20021212	WO 2001US41748	A	20010817	200301
			US 2002926746	A	20020606	

JP 2004506657 W 20040304 WO 2001US41748 A 20010817 200417
 JP 2002519605 A 20010817
 AU 773081 B2 20040513 AU 200196851 A 20010817 200462

Priority Applications (No Type Date): US 2000225821 P 20000817; US
 2002926746 A 20020606

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200214477 A2 E 30 C12N-000/00

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA
 CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
 JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH
 PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR
 IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200196851 A A61K-031/00 Based on patent WO 200214477

EP 1254209 A2 E C12N-001/00 Based on patent WO 200214477

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT
 LI LT LU LV MC MK NL PT RO SE SI TR

US 20020187943 A1 A61K-031/7048

JP 2004506657 W 65 A61K-031/191 Based on patent WO 200214477

AU 773081 B2 A61K-031/00 Previous Publ. patent AU 200196851
 Based on patent WO 200214477

Abstract (Basic): WO 200214477 A2

Abstract (Basic):

NOVELTY - Method for appetite suppression, inhibition of
 cytoplasmic citrate lyase and fat catabolism and increasing lean body
 mass involves administration of **hydroxycitric** acid (HCA) or
 forskolin in combination with garcinol and/or anthocyanin.

DETAILED DESCRIPTION - Other INDEPENDENT CLAIMS are also included
 for the following:

(1) method for increasing anti-oxidant activity of garcinol
 involves administration of HCA, garcinol and anthocyanin; and

(2) process of manufacturing HCA, garcinol and anthocyanin from
 fruits of *Garcinia* sp. involves extraction either with organic solvents
 or supercritical carbon dioxide.

ACTIVITY - Anorectic; Antitumor.

SKH-1 mice were divided into 4 groups. Group (1) was a control
 group, group (2) was administered with garcinol (0.05 wt.%), group (3)
 with HCA (1 wt.%) and group (4) with garcinol (0.05 wt.%) and HCA (1
 wt.%).

The mice of group 1/2/3/4 were measured on week 10 for body weight
 (gm), food consumption (gm/mouse/day) and water consumption
 (ml/mouse/day) and were found to be 37+/-1.49 / 36.4+/-0.55 /
 36.8+/-0.33 / 34.9+/-0.88, 5.16+/-0.25 / 5.26+/-0.17 / 6.93+/-0.21 /
 9.31+/-1.12, and

3.8+/-0.22 / 3.73+/-0.17 / 3.84+/-0.09 / 3.94+/-0.08 respectively.

MECHANISM OF ACTION - Citrate lyase inhibitor.

USE - In weight-loss therapy for suppressing appetite, inhibiting
 cytoplasmic citrate lyase and for increasing fat catabolism and lean
 body mass (claimed).

The garcinol alone have chemopreventive properties in animal tumor
 model.

ADVANTAGE - The HCA enhances the biological potential and
 anti-oxidant activity of the garcinol and anthocyanin.

pp; 30 DwgNo 0/19

7/AB/21 (Item 6 from file: 351)
 DIALOG(R) File 351:Derwent WPI
 (c) 2004 Thomson Derwent. All rts. reserv.

014245316

WPI Acc No: 2002-066016/200209

XRAM Acc No: C02-019572

Treating or ameliorating **hypertension** or high **blood**

pressure involves orally administering (-)-**hydroxycitric** acid

Patent Assignee: CLOUATRE D L (CLOU-I); DUNN J M (DUNN-I)

Inventor: CLOUATRE D L; DUNN J M

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20010044469	A1	20011122	US 2000181285	A	20000209	200209 B
			US 2001781491	A	20010213	

Priority Applications (No Type Date): US 2000181285 P 20000209; US 2001781491 A 20010213

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
US 20010044469	A1		6	A61K-031/194	Provisional application US 2000181285

Abstract (Basic): US 20010044469 A1

Abstract (Basic):

NOVELTY - Treating or ameliorating **hypertension** or high **blood pressure** involves administering orally (-)-**hydroxycitric** acid.

ACTIVITY - Hypotensive; antidiabetic.

Ten-week old male rats were placed on a moderate fat diet (30% of calories) for 60 days. These rats were fed water or potassium **hydroxycitrate** (KHCA) (0.33 mmols/kg) twice daily by gastric intubation. Five animals were used as controls and two different formulas of KHCA were provided to five animals each. At the termination of the trial, the differences between control (5 data points) and active (10 data points) were then analyzed according to student's T test. There was no significant difference between control and the KHCA groups with regard to non-esterified fatty acids (NEFA). Insulin levels in the animals given KHCA was significantly lower than in controls, with a one-tailed P value of 0.0306; in the two-tailed test, P was just short of significance at 0.0612 because of the small number of animals. Corticosterone levels were also very significantly lower in the KHCA groups than in control, with a one-tailed P value of 0.0013 and a two-tailed P value of 0.0026. Both of these factors played a role in the clinical findings of lowered **blood pressure** in **hypertensive** individuals.

MECHANISM OF ACTION - None given in the source material.

USE - For treating or ameliorating **hypertension** or high **blood pressure** (claimed); for treating patients suffering from salt-sensitive **hypertension** and insulin resistance due to chronic hyperinsulinemia.

ADVANTAGE - The (-)-**hydroxycitric** acid lowers elevated insulin and elevated stress hormone levels (preferably glucocorticoid levels) and thus reduces the elevated **blood pressure** level without any side effects. The treatment provides an improvement in the **blood pressure** metabolism that shows evidence of dysregulation.

pp; 6 DwgNo 0/0

?